

# Observations on the direct amidocyclopropanation of alkenes using organozinc carbenoids

William B. Motherwell,<sup>a,\*</sup> Guillaume Bégis,<sup>a</sup> David E. Cladingboel,<sup>b</sup> Laure Jerome<sup>a</sup> and Tom D. Sheppard<sup>a</sup>

<sup>a</sup>Department of Chemistry, Christopher Ingold Laboratories, University College London, 20 Gordon Street, London WC1H 0AJ, UK

<sup>b</sup>AstraZeneca R&D Charnwood, Bakewell Road, Loughborough LE11 5RH, UK

Received 22 January 2007; revised 28 February 2007; accepted 2 March 2007

Available online 12 March 2007

**Abstract**—A series of amidocyclopropanes were prepared by direct amidocyclopropanation of alkenes, using organozinc carbenoids generated from readily available diethoxymethylamides. The amidocyclopropanation of monosubstituted alkenes led to selective formation of the *trans*-amidocyclopropane in most cases, but with more substituted alkenes, the stereochemical outcome of the cyclopropanation reactions was unpredictable. The amidocyclopropane products can be readily elaborated to structurally interesting cyclopropane containing amino acids or amino alcohols.

© 2007 Elsevier Ltd. All rights reserved.

## 1. Introduction

The aminocyclopropyl unit is present in a wide range of biologically active natural products and pharmaceuticals.<sup>1</sup> Traditional approaches to the synthesis of aminocyclopropanes include the Curtius rearrangement of cyclopropylcarboxylic acids,<sup>2</sup> the reduction of nitrocyclopropanes,<sup>3</sup> the reductive amination of cyclopropanone acetals<sup>4</sup> and the cyclopropanation of enamines.<sup>5</sup> More recently, de Meijere has demonstrated a new titanium mediated cyclopropanation of amides or nitriles using 1,2-dimetallic derivatives of monosubstituted alkenes.<sup>6</sup> By way of contrast however, the search for simple and experimentally convenient methods for the direct addition of heteroatom substituted carbenoids to unactivated alkenes has proven to be more elusive, with direct alkoxy-cyclopropanation and aminocyclopropanation requiring the use of such reagents as stoichiometric Fischer carbene complexes.<sup>7</sup> As an extension of our earlier studies on the cyclopropanation of alkenes using organozinc carbenoids prepared from simple carbonyl compounds<sup>8</sup> or their derived acetals,<sup>9</sup> we have previously demonstrated that orthoformates are useful precursors for direct alkoxy-cyclopropanation.<sup>10</sup> More recently, we have also shown that diethoxymethylpyrrolidinone can be used for generation of an amidosubstituted organozinc carbenoid,<sup>11</sup> and that selection of a chiral oxazolidinone congener leads to an asymmetric version of this amidocyclopropanation reaction.<sup>12</sup> In the present paper, we wish to report, in full, our detailed observations on the scope and limitations of simple achiral


diethoxymethylamide carbenoid precursors for the construction of densely functionalised amidocyclopropanes.

## 2. Results and discussion

From a mechanistic standpoint, we envisaged that the evolution of a suitably functionalised amidoorganozinc carbenoid from a diethoxymethylamide **1** could proceed as shown in Scheme 1. Thus, coordination of a Lewis acid (either ZnCl<sub>2</sub> or Me<sub>3</sub>SiCl) to one of the ethoxy groups of the amide **1** leads to the formation of cation **2**, which can be reduced by two electron delivery from metallic zinc to give the organozinc derivative **3**. Lewis acid mediated S<sub>N</sub>1 displacement of the remaining ethoxy group by chloride then formally leads to the organozinc carbenoid, which could exist as either the tetrahedral form **4** or the planar iminium form **5**.


The diethoxymethylamide carbenoid precursors **12–17** were initially prepared by heating the corresponding amides **6–11** in a large excess of triethyl orthoformate in the presence of a catalytic amount of aluminium chloride according to a literature procedure (Scheme 2 and Table 1).<sup>13</sup> However, this method is inconvenient, particularly on larger scales, due to the difficulty in removing the large excess of orthoformate, and hence alternative methods were investigated. We found that the diethoxymethyl derivative of pyrrolidinone **6** (entry 1) could be conveniently prepared on a 10 g scale using only 2.6 equiv of triethyl orthoformate in the presence of chlorotrimethylsilane and a catalytic amount of triphenylphosphine at room temperature. After purification by distillation, the dialkoxymethylactam **12** was obtained in 61% yield. In a similar fashion, diethoxymethylloxazolidinone **13** (entry 2) was obtained in 60% yield (10 g scale) using

\* Corresponding author. Tel.: +44 (0)2076797533; fax: +44 (0)2076797524; e-mail: [w.b.motherwell@ucl.ac.uk](mailto:w.b.motherwell@ucl.ac.uk)



Scheme 1.

2.6 equiv of orthoester and a catalytic quantity of acetyl chloride. This latter procedure is the most convenient but was not generally applicable to the preparation of the other diethoxymethyl derivatives. It is notable that in this case the starting oxazolidinone is insoluble in the reaction mixture and gradually dissolves as the reaction progresses, and this gradual dissolution may well be important for the success of the reaction. The yields are essentially comparable



**Scheme 2.** Reagents and conditions: (a)  $(\text{EtO})_3\text{CH}$ ,  $\text{AlCl}_3$ ,  $155^\circ\text{C}$  (Method A); (b)  $(\text{EtO})_3\text{CH}$ , cat.  $\text{Me}_3\text{SiCl}$ , cat.  $\text{PPh}_3$ ,  $\text{CH}_2\text{Cl}_2$ , rt (Method B); (c)  $(\text{EtO})_3\text{CH}$ , cat.  $\text{AcCl}$ , rt (Method C).

Table 1

Entry	Amide	Product	Yield
1			70, <sup>a</sup> 61 <sup>b</sup>
2			67, <sup>a</sup> 60 <sup>c</sup>
3			63 <sup>a</sup>
4			93 <sup>a</sup>
5			71 <sup>a</sup>
6			18 <sup>a</sup>


<sup>a</sup> Method A.

<sup>b</sup> Method B.

<sup>c</sup> Method C.

to the  $\text{AlCl}_3$  catalysed reactions, and these methods avoid the requirement for a large excess of triethyl orthoformate and the associated purification problems which then arise.



















With the required diethoxymethylamides in hand, the amidocyclopropanation of a wide range of alkenes was investigated using zinc, chlorotrimethylsilane and zinc chloride (Scheme 3 and Table 2). In the initial reactions, zinc amalgam was employed as the metal source. Although easily handled, the amalgam is undesirable due to the toxicity and environmental issues associated with the use of mercury and its salts. Moreover, we have also observed that the zinc amalgam has a tendency to form hard spheres during the course of the cyclopropanation reactions, which can lead to variable yields, presumably due to the large decrease in the available surface area of the metal. To this end, we were keen to investigate alternative metal sources, and the use of zinc dust, together with a catalytic quantity of copper(I) chloride, was found to be a perfectly acceptable substitute, giving the amidocyclopropanes in comparable yields (entry 1). The formation of hard metal spheres during the course of the reactions is also no longer observed.



Scheme 3.



















The cyclopropane products **39–65** were obtained in moderate to good yields with a wide variety of alkenes. All of the carbenoid precursors could be employed in the amidocyclopropanation reaction with the exception of diethoxymethylphthalimide **14**. Since the phthalimide functional group is known to be reduced under dissolving metal conditions,<sup>14</sup> this observation is perhaps unsurprising. As anticipated, the amidocyclopropanation of electron-rich alkenes (entries 8 and 10) proceeded in higher yield than the amidocyclopropanation of electron-deficient alkenes (entry 9) and in the cyclopropanation of diene **38** (entry 23), chemoselective cyclopropanation of the more electron-rich alkene was observed. In terms of the steric environment, mono (entries 1–3, 8, 10–13, 16, 18, 19 and 24–26), di (entries 4–6, 9, 14, 15, 20, 21 and 27), tri (entries 7, 22 and 23) and tetrasubstituted (entry 17) alkenes were all readily cyclopropanated under the reaction conditions and a variety of functional groups including esters, ethers, halides and silyl groups were tolerated. In the case of highly volatile alkenes (entry 17), it was more effective to carry out the cyclopropanation reaction

Table 2

Entry	Alkene	Product (major)	<i>trans:cis</i> or <i>exo:endo</i>	Yield
1	 <b>18</b>	 <b>39</b>	11.5:1	88, <sup>a</sup> 83 <sup>b</sup>
2	 <b>19</b>	 <b>40</b>	1.1:1	70 <sup>a,c</sup>
3	 <b>20</b>	 <b>41</b>	>95:5	61 <sup>a</sup>
4	 <b>21</b>	 <b>42</b>	—	83 <sup>a</sup>
5	 <b>22</b>	 <b>43</b>	1:1	52 <sup>a</sup>
6	 <b>23</b>	 <b>44</b>	10:1	66 <sup>a</sup>
7	 <b>24</b>	 <b>45</b>	1.3:1	63 <sup>a</sup>
8	 <b>25</b>	 <b>46</b>	2:1	57 <sup>a</sup>
9	 <b>26</b>	 <b>47</b>	1:1	9 <sup>a</sup>

(continued)

Table 2. (continued)

Entry	Alkene	Product (major)	<i>trans:cis</i> or <i>exo:endo</i>	Yield
10	 <b>27</b>	 <b>48</b>	2:1	56 <sup>a</sup>
11	 <b>28</b>	 <b>49</b>	>95:5	58 <sup>a</sup>
12	 <b>29</b>	 <b>50</b>	>95:5	39 <sup>a</sup>
13	 <b>30</b>	 <b>51</b>	7:1	66 <sup>b</sup>
14	 <b>31</b>	 <b>52</b>	(>5:95) <sup>e</sup>	66 <sup>b</sup>
15	 <b>32</b>	 <b>53</b>	1:1	28 <sup>b</sup>
16	 <b>33</b>	 <b>54</b>	1:2	19 <sup>b</sup>
17	 <b>34</b>	 <b>55</b>	—	22, <sup>b</sup> 36 <sup>b,d</sup>
18	 <b>18</b>	 <b>56</b>	15:1	57 <sup>b</sup>

(continued)

Table 2. (continued)

Entry	Alkene	Product (major)	<i>trans:cis</i> or <i>exo:endo</i>	Yield
19			>95:5	46 <sup>a</sup>
20			2.6:1	34 <sup>b</sup>
21			(1:16) <sup>c</sup>	11 <sup>b</sup>
22			—	58 <sup>b</sup>
23			1:11	38 <sup>b</sup>
24			6:1	56 <sup>a</sup>
25			13.5:1	14 <sup>a</sup>
26			—	34 <sup>b</sup>

(continued)

Table 2. (continued)

Entry	Alkene	Product (major)	<i>trans:cis</i> or <i>exo:endo</i>	Yield
27			(>5:95) <sup>c</sup>	22 <sup>b</sup>

<sup>a</sup> Zn(Hg) method.<sup>b</sup> Zn/CuCl method.<sup>c</sup> The carbenoid precursor was added by syringe pump over 2 h.<sup>d</sup> Reaction carried out at room temperature.<sup>e</sup> Selectivities in parentheses refer to purified material.

at room temperature. The stereochemistry of the major products was assigned on the basis of <sup>1</sup>H NMR coupling constants and simple proton decoupling experiments where required. In most cases, a preference for the formation of the less-hindered *trans*-amidocyclopropane was observed. However, the overall trends in selectivity from substrate to substrate are difficult to rationalise. In general, monosubstituted alkenes tend to favour the formation of the *trans* isomer with varying degrees of selectivity with larger substituents leading to a higher preference for *trans*-cyclopropanation. Interestingly, the presence of an allylic ether group reversed this selectivity (entry 16), but an allylic or vinylic ester did not (entries 8, 10 and 13). This may indicate that coordination of the ether oxygen to the zinc carbenoid during cyclopropanation can influence the stereochemical outcome and we might expect this to be more favourable for an ether than an ester. The trends for more substituted alkenes are much more difficult to rationalise. Cyclohexene **23** showed a strong preference for the formation of the *exo*-cyclopropane (entry 6), whereas for indene **31** the reverse was true (entries 14 and 27). Apparently similar systems such as methylcyclohexene **24** and carene **37** showed contrasting selectivities in the cyclopropanation reaction (entries 7 and 22). A speculative explanation using a quadrant model (Fig. 1) in which one quadrant (**A**) is largely unhindered, but the adjacent quadrant (**B**) is sterically congested might help to explain these results. Thus a monosubstituted alkene ( $R^2=H$ ) fits into the 'pocket' with the  $R^1$  substituent occupying the unhindered quadrant **A** in transition state (i). When a second substituent is present on the alkene ( $R^2\neq H$ ), the larger steric hindrance in quadrant **B** can lead to the *cis* transition state (ii) becoming the favoured pathway, in which the two alkyl groups occupy quadrants **C** and **D** where there is only moderate steric hindrance.

A possible transition state in line with such a model is shown in Figure 2, in which the zinc atom is located in quadrant **D**, and the orientation of the pyrrolidine ring is controlled by coordination of the lactam oxygen to the metal centre. This places the lactam carbonyl in quadrant **C** and the methylene adjacent to the nitrogen in quadrant **B**, leaving quadrant **A** largely empty. Thus, a monosubstituted alkene ( $R^2=H$ ) can approach the carbenoid relatively easily with the  $R^1$  group located in quadrant **A**, leading to a preference for *trans*-cyclopropane formation (i). With more substituted alkenes ( $R^2\neq H$ ), the unfavourable interaction between the lactam hydrogen atoms and  $R^2$  in the *exo* transition state (i) leads to




Figure 1.





Figure 2.


a preference for the *endo* transition state (ii) in which  $R^1$  is close to the zinc atom and  $R^2$  close to the lactam carbonyl group.

The use of a large excess of chlorotrimethylsilane in the reaction precluded direct amidocyclopropanation of allylic alcohols, but a preliminary experiment (Scheme 4) with allyl benzene **18** demonstrated that the cyclopropane **39** could be produced in the absence of the silicon electrophile by employing a larger excess of zinc chloride (30% conversion). When these alternative conditions were applied to the cyclopropanation of allyl alcohol, amidocyclopropyl alcohol **67** was obtained in low yield (8%, diastereomeric ratio *trans*:*cis* 2:1). However, when 2-cyclohexen-1-ol **68** was cyclopropanated under the same conditions, the only isolated product was the ethyl ether **69**, again in 8% yield. Cyclopropane ether **69** is probably formed by initial displacement of the hydroxy group with ethanol under the Lewis acidic conditions and then subsequent cyclopropanation of the allylic ether **70**. Alkene **70** was synthesised by alkylation of the alcohol **68**, and cyclopropanated under the same conditions to give the same cyclopropane **69** in 20% yield (diastereomeric ratio >8:1). Interestingly, the ethyl ether appears to direct the approach of the organozinc carbenoid to the same face of the ring.<sup>15</sup> The *exo*-cyclopropane is also formed selectively in a similar fashion to the cyclopropanation of cyclohexene above (Table 2, entry 6).




Scheme 4. Reagents and conditions: (a) **12**,  $ZnCl_2$ , Zn, CuCl,  $Et_2O$ , 8% (**67**), 8% (**69** from **68**), 20% (**69** from **70**); (b) NaH, DMF, EtI, 33% based on recovered **68**.

The cyclopropanes formed in these reactions are suitable for further elaboration into derivatives of potential utility for incorporation as rigid conformational locks in a wide variety of systems, such as chiral ligands or drug molecules (Scheme 5). The oxazolidinone ring in cyclopropane **57** was opened under basic conditions to yield the aminoalcohol **71**, which was BOC protected and oxidised to the corresponding *N*-cyclopropylglycine derivative **73**. Similarly, the benzoxazolidine ring in **65** can be opened using Super Hydride<sup>16</sup> to give the indenocyclopropylcatecholamine **74** in moderate yield. The cyclopropylsilane **50** was oxidised under Tamao–Fleming conditions to give the corresponding amidocyclopropanol **75** in 35% yield. These examples provide a brief illustration of the interesting cyclopropylamino acid and aminoalcohol units that can readily be prepared using amidoorganozinc carbenoids. Densely functionalised cyclopropylamino acid **73** was obtained in only four steps from the cheap commercially available alkene **20**.



Scheme 5. Reagents and conditions: (a) LiOH, EtOH,  $H_2O$ , 49%; (b)  $BOC_2O$ ,  $Et_3N$ ,  $CH_2Cl_2$ , 72%; (c)  $KMnO_4$ , NaOH,  $tBuOH$ ,  $H_2O$ , 84%; (d)  $LiEt_3BH$ , THF, 34%; (e) TBAF, THF, rt then 30%  $H_2O_2$ ,  $KHCO_3$ , MeOH, 35%.

Finally, from a practical viewpoint, it would be much more convenient to avoid the need for preparation of the orthoester derived carbenoid precursors. As both the introduction of the diethoxymethyl group itself and the cyclopropanation reaction are carried out in the presence of Lewis acids, we decided to investigate whether the two processes could be combined into a one-pot reaction (Scheme 6). Thus, triethyl orthoformate was added dropwise to a mixture of alkene **18**, oxazolidinone **7**, zinc, copper chloride, chlorotrimethylsilane and zinc chloride and to our delight, the amidocyclopropane was obtained directly in 33% yield, comparable to the 38% overall yield obtained in the separate steps described



**Scheme 6.** Reagents and conditions: (a) **7**, (EtO)<sub>3</sub>CH, Me<sub>3</sub>SiCl, ZnCl<sub>2</sub>, Zn, CuCl, Et<sub>2</sub>O, 33%.

above. Although, the alkoxy-cyclopropanation of alkenes with orthoformates proceeds under similar conditions,<sup>10</sup> no alkoxy-cyclopropane was observed, implying that the reaction between the amide and orthoester is overwhelmingly favoured. We are currently optimising this new approach and investigating its scope for the direct preparation of amidocyclopropanes from a wide range of amide precursors.

### 3. Conclusion

In summary, the amidocyclopropanation of alkenes using di-alkoxymethylamides as zinc carbenoid precursors constitutes an effective method for functionalised cyclopropane preparation, and enables a range of highly functionalised aminocyclopropane derivatives to be accessed, which cannot readily be obtained using existing methods. These amidocyclopropane units can be readily elaborated into cyclopropyl containing aminoalcohol or amino acid motifs.

### 4. Experimental

#### 4.1. General

All reactions were carried out in oven-dried glassware under a nitrogen atmosphere unless otherwise indicated. Diethyl ether, tetrahydrofuran, toluene and dichloromethane were used following purification from an anhydrous engineering zeolite drying apparatus. Methanol and ethanol were distilled from magnesium turnings and iodine. Anhydrous dimethylformamide was obtained from the Aldrich chemical company. Triethylamine was distilled from potassium hydroxide before use. Chlorotrimethylsilane was distilled from calcium hydride immediately prior to use. Styrene, cyclohexene, indene, 1,2-dihydronaphthalene and 3-carene were distilled before use. All other chemicals were used as supplied unless otherwise indicated. Column chromatography was carried out using BDH (40–60 μm) silica gel and analytical thin layer chromatography was carried out using Merck Kieselgel aluminium-backed plates coated with silica gel. Components were visualised using combinations of ultra-violet lights, iodine, ceric ammonium molybdate, phosphomolybdic acid and potassium permanganate. Melting points were determined using a Reichert hot-stage apparatus and are uncorrected. Optical rotations were measured using a Perkin–Elmer 241 (sodium D-line, 529 nm) polarimeter and [α]<sub>D</sub> values are given in 10<sup>-1</sup> deg cm<sup>2</sup> g<sup>-1</sup>, concentration (*c*) in g/100 mL. Infrared (IR) spectra were recorded on a Perkin–Elmer 1605 Fourier transform spectrometer and were recorded as thin films (NaCl plate). <sup>1</sup>H NMR spectra were recorded at 300 MHz on a Bruker AMX300 spectrometer, at 400 MHz on a Bruker AMX400 spectrometer or at 500 MHz on a Bruker Avance 500 spectrometer in the stated solvent using residual protic solvent CHCl<sub>3</sub> (δ=7.26 ppm,

s), DMSO (δ=2.56 ppm, qn) or D<sub>2</sub>O (4.79, s) as the internal standard. Chemical shifts are quoted in ppm using the following abbreviations: s, singlet; d, doublet; t, triplet; q, quartet; qn, quintet; m, multiplet; br, broad or a combination of these. The coupling constants (*J*) are measured in Hertz. <sup>13</sup>C NMR spectra were recorded at 75 MHz on a Bruker AMX300 spectrometer, at 100 MHz on a Bruker AMX400 spectrometer or at 125 MHz on a Bruker Avance 500 spectrometer in the stated solvent using the central reference of CHCl<sub>3</sub> (δ=77.0 ppm, t), DMSO (δ=39.52 ppm, septet) as the internal standard. Chemical shifts are reported to the nearest 0.1 ppm. Mass spectra and elemental analysis were performed at the Department of Chemistry, University College London.

**4.1.1. 2,3-Dihydro-1-isoindolinone **9**.**<sup>14</sup> Tin powder (41.7 g, 0.35 mol, 2.6 equiv) was added to a vigorously stirred suspension of phthalimide (20 g, 0.14 mol, 1 equiv) in a mixture of glacial acetic acid (100 mL) and concentrated hydrochloric acid (50 mL). The reaction mixture was heated at reflux for 2 h and then filtered hot. The filtrate was concentrated and the residue partitioned between dichloromethane (300 mL) and water (150 mL). The organic layer was separated and the aqueous layer extracted with dichloromethane (2 × 50 mL). The combined organic extracts were dried (MgSO<sub>4</sub>), filtered and concentrated. The crude product was purified twice by flash column chromatography (EtOAc) and then triturated in toluene to give the lactam **9** (4.2 g, 31.5 mmol, 23%) as a white solid; mp 149–150 °C (lit.<sup>14</sup> 150–151 °C); IR (CH<sub>2</sub>Cl<sub>2</sub>): ν<sub>max</sub> 3214 (br s), 1658 (s) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.48 (s, 2H, CH<sub>2</sub>), 7.18 (br s, 1H, NH), 7.47–7.60 (m, 4H, Ar-H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 45.8, 123.2, 123.6, 128.0, 131.7, 132.6, 143.7, 172.6.

**4.1.2. General procedure for synthesis of diethoxymethylamides **12–17**.** A mixture of amide (6.7 mmol), aluminium chloride (1.0 mmol, 0.15 equiv) and triethyl orthoformate (22 mL, 0.13 mol, 20 equiv) was heated at 155 °C for 24–72 h. The reaction mixture was allowed to cool to room temperature and then quenched with saturated aqueous sodium bicarbonate (25 mL). The aqueous phase was extracted with diethyl ether (50 mL then 2 × 25 mL) and the combined organic extracts were washed with brine (25 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated. The crude product was purified by flash column chromatography.

**4.1.2.1. N-Diethoxymethylpyrrolidin-2-one **12** (alternative procedure).** Chlorotrimethylsilane (1.5 mL, 11.7 mmol) was added dropwise to a stirred solution of pyrrolidinone (10 g, 117.6 mmol), triethyl orthoformate (50 mL, 300.6 mmol) and triphenylphosphine (50 mg, 0.2 mmol) in dichloromethane (200 mL) under nitrogen. The resulting solution was stirred overnight at room temperature then poured into water (70 mL) and saturated sodium bicarbonate (50 mL). The layers were separated and the organic layer washed with brine (50 mL), dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. The residue was distilled under reduced pressure to give **12** as a colourless liquid (bp 101–103 °C at 3 mbar [lit.<sup>17</sup> 84–86 °C at 1 mmHg], 13.42 g, 61%).

**4.1.2.2. N-Diethoxymethyl-2-oxazolidinone **13** (alternative procedure).** Acetyl chloride (1 mL, 14 mmol)

was added to a stirred suspension of oxazolidin-2-one (10 g, 113.8 mmol) in triethyl orthoformate (50 mL, 300.6 mmol). The suspension was stirred overnight at room temperature and then the reaction mixture was distilled under reduced pressure to give diethoxymethylloxazolidinone as a colourless liquid (120–122 °C at 0.9 mmHg, 12.9 g, 60%).

**4.1.2.3. *N*-Diethoxymethylpyrrolidin-2-one 12.** Pale yellow oil; IR (film):  $\nu_{\max}$  2977 (s), 2897 (m), 1693 (s)  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  1.20 (t,  $J=7.0$ , 6H, 2×Me), 1.96–2.03 (m, 2H,  $\text{CH}_2\text{CH}_2\text{N}$ ), 2.41 (t,  $J=8.2$ , 2H,  $\text{CH}_2\text{CON}$ ), 3.42 (t,  $J=7.3$ ,  $\text{CH}_2\text{N}$ ), 3.48 (dq,  $J=9.4$ , 7.0, 2H, 2×CHHMe), 3.62 (dq,  $J=9.4$ , 7.0, 2H, 2×CHHMe), 5.87 (s, 1H, CH);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ ):  $\delta$  14.5, 17.8, 31.4, 40.5, 61.9, 98.8, 175.2; MS (FAB)  $m/z$  (%): 210 (M+Na, 100), 142 (25); HRMS: M+Na, found 210.11009.  $\text{C}_9\text{H}_{17}\text{NO}_3\text{Na}$  requires 210.11061.

**4.1.2.4. *N*-Diethoxymethyl-2-oxazolidinone 13.** Pale yellow oil; IR (film):  $\nu_{\max}$  2979 (w), 2904 (w), 1747 (s)  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  1.25 (t,  $J=7.1$ , 6H, Me), 3.53–3.73 (m, 6H,  $\text{CH}_2\text{N}$  and 2× $\text{CH}_2\text{Me}$ ), 4.39 (t,  $J=8.2$ , 2H,  $\text{CH}_2\text{CH}_2\text{N}$ ), 5.74 (s, 1H, CH);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  14.8, 38.6, 62.6, 62.8, 101.3, 157.4; MS (CI+)  $m/z$  (%): 190 (M+H, 2), 144, 100, 116 (12), 103 (100), 75 (14), 44 (16); HRMS: M+H, found 190.10785.  $\text{C}_8\text{H}_{16}\text{NO}_4$  requires 190.10793.

**4.1.2.5. *N*-Diethoxymethylphthalimide 14.** White solid; mp 73–74 °C (lit.<sup>18</sup> 73 °C); IR (film):  $\nu_{\max}$  2977 (w), 1774 (m), 1720 (s), 1694 (w), 1469 (w)  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  1.25 (t,  $J=7.1$ , 6H, 2× $\text{CH}_3$ ), 3.62 (dq,  $J=9.4$ , 7.1, 2H, 2×CHHMe), 3.77 (dq,  $J=9.4$ , 7.1, 2H, 2×CHHMe), 6.09 (s, 1H, CH), 7.68–7.77 (m, 2H, Ar-H), 7.82–7.90 (m, 2H, Ar-H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ ):  $\delta$  14.8, 63.4, 99.8, 123.6, 131.7, 134.3, 166.6; MS (CI+)  $m/z$  (%): 249 ( $\text{M}^+$ , 100), 175 (56), 147 (78); HRMS:  $\text{M}^+$ , found 249.09952.  $\text{C}_{13}\text{H}_{15}\text{NO}_4$  requires 249.1001.

**4.1.2.6. 2-Diethoxymethyl-2,3-dihydro-1-isoindolinone 15.** Brown oil; IR (film):  $\nu_{\max}$  2977 (m), 2932 (w), 1694 (s), 1620 (w), 1470 (m), 1452 (w)  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  1.25 (t,  $J=7.0$ , 6H, 2×Me), 3.57 (dq,  $J=9.5$ , 7.0, 2H, 2×CHHCH<sub>3</sub>), 3.74 (dq,  $J=9.5$ , 7.0, 2H, 2×CHHCH<sub>3</sub>), 4.49 (s, 2H,  $\text{CH}_2\text{N}$ ), 6.23 (s, 1H, CH), 7.45–7.51 (m, 2H, Ar-H), 7.58 (t,  $J=7.5$ , 1H, Ar-H), 7.87 (d,  $J=7.5$ , 1H, Ar-H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  14.8, 44.2, 62.5, 99.2, 123.2, 124.1, 128.0, 132.0, 132.1, 142.0, 168.9; MS (CI+)  $m/z$  (%): 236 (M+H, 6), 190 (44), 134 (59), 103 (46); HRMS: M+H, found 236.12847.  $\text{C}_{13}\text{H}_{18}\text{NO}_3$  requires 236.12866.

**4.1.2.7. 3-(Diethoxymethyl)benzoxazolin-2-one 16.** Red oil; IR (film):  $\nu_{\max}$  2980, 1786 (s), 1625 (w);  $^1\text{H}$  NMR (400 MHz, DMSO):  $\delta$  1.16 (t,  $J=7.1$ , 6H, 2×Me), 3.60 (dq,  $J=9.6$ , 7.1, 2H, 2×CHHMe), 3.73 (dq,  $J=9.6$ , 7.1, 2H, 2×CHHMe), 6.11 (s, 1H, CH), 7.16–7.24 (m, 2H, Ar), 7.34–7.39 (m, 2H, Ar);  $^{13}\text{C}$  NMR (100 MHz, DMSO):  $\delta$  14.6, 62.4, 101.4, 110.0, 111.9, 122.9, 124.2, 127.7, 141.9, 152.4; MS (CI+)  $m/z$  (%): 237 ( $\text{M}^+$ , 70), 205 (75), 193 (100), 104 (70); HRMS: M+H, found 238.10832.  $\text{C}_{12}\text{H}_{16}\text{NO}_4$  requires 238.10793.

**4.1.2.8. *N*-Benzyl-*N*-diethoxymethylacetamide 17.** Yellow oil; IR (film):  $\nu_{\max}$  2978 (m), 2933 (w), 1670 (s), 1497 (w)  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz, 353 K, DMSO):  $\delta$  1.10 (t,  $J=7.1$ , 6H, 2×Me), 2.05 (s, 2.1H,  $\text{COCH}_3$ ), 2.98 (s, 0.9H,  $\text{COCH}_3$ ), 3.37–3.63 (m, 4H, 2× $\text{CH}_2\text{CH}_3$ ), 4.41 (s, 0.6H,  $\text{PhCH}_2\text{N}$ ), 4.50 (s, 1.4H,  $\text{PhCH}_2\text{N}$ ), 5.58 (br s, 0.3H, CH), 6.00 (br s, 0.7H, CH), 7.16–7.35 (m, 5H, Ar-H);  $^{13}\text{C}$  NMR (major rotamer, 100 MHz, 353 K, DMSO):  $\delta$  14.0, 21.4, 43.7, 61.2, 102.2, 125.8, 126.7, 127.3, 138.9, 169.0; MS (CI+)  $m/z$  (%): 252 (M+H, 3), 206 (62), 150 (100), 103 (61), 91 (68); HRMS: M+H, found 252.16019.  $\text{C}_{14}\text{H}_{22}\text{NO}_3$  requires 252.15997.

**4.1.3. Benzyl dimethyl(vinyl)silane 29.** A solution of benzyl chloride (1.15 mL, 10 mmol) in dry diethyl ether (10 mL) was added dropwise to a mixture of magnesium turnings (0.24 g, 10 mmol) and iodine (two crystals) in dry diethyl ether (10 mL) under nitrogen. The reaction mixture was stirred for 1 h and dimethylvinylchlorosilane (1.64 mL, 12 mmol) was added dropwise. The reaction mixture was heated at reflux for 16 h and then quenched carefully with saturated aqueous ammonium chloride (20 mL). The organic layer was separated and the aqueous layer was extracted with diethyl ether (2×20 mL). The combined organic extracts were dried ( $\text{MgSO}_4$ ), filtered and concentrated in vacuo. The crude product was purified by flash column chromatography (petrol) to give **29** as a colourless oil (1.09 g, 62%); IR ( $\text{CDCl}_3$ ):  $\nu_{\max}$  3024, 2957, 2893 (w), 1601, 1493 (s), 1452 (w), 1404  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  0.57 (s, 6H, 2×Me), 2.15 (s, 2H,  $\text{CH}_2$ ), 5.67 (dd,  $J=20.3$ , 3.8, 1H,  $\text{CH}=\text{CHH}$ ), 5.97 (dd,  $J=14.7$ , 3.8, 1H,  $\text{CH}=\text{CHH}$ ), 6.13 (dd,  $J=20.3$ , 14.7, 1H,  $\text{CH}=\text{CH}_2$ ), 6.99–7.02 (m, 2H, Ar-H), 7.05–7.09 (m, 1H, Ar-H), 7.18–7.23 (m, 2H, Ar-H);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ ):  $\delta$  -3.7, 25.8, 124.0, 128.1, 128.2, 132.2, 138.2, 139.9; MS (EI)  $m/z$  (%): 176 ( $\text{M}^+$ , 13), 91 (17), 85 (100); HRMS:  $\text{M}^+$ , found 176.10155.  $\text{C}_{11}\text{H}_{16}\text{Si}$  requires 176.10158.

**4.1.4. Ethyl 2-allyloxyacetate 33.**<sup>19</sup> Sodium hydride (60% dispersion in mineral oil, 1.76 g, 44 mmol) was added portionwise to a solution of ethyl glycolate (4.16 g, 40 mmol) in anhydrous DMF (20 mL) under nitrogen at 0 °C. After stirring for 30 min, allyl bromide (3.8 mL, 44 mmol) was added dropwise and the reaction mixture was allowed to warm to room temperature. After stirring for 90 min at room temperature, water (20 mL) was added and the reaction mixture extracted with ether (3×30 mL). The combined organic layers were washed with brine, dried ( $\text{MgSO}_4$ ) and concentrated and the residue was distilled to afford two fractions: Fraction 1 (bp 52–54 °C, 14 mbar) contained a mixture of the alkene **33** and DMF (2:1 ratio), Fraction 2 (bp 64–65 °C, 10 mbar, lit.<sup>19</sup> 70–74 °C at 20 mmHg) contained the alkene **33**. The two fractions were combined and dissolved in ether (30 mL) and washed with saturated lithium chloride (2×20 mL), dried ( $\text{MgSO}_4$ ) and concentrated to give the alkene as a colourless liquid (1.37 g, 9.5 mmol, 24%); IR (film):  $\nu_{\max}$  2984, 2941, 2909, 2876, 1755 (s)  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  1.29 (t,  $J=7.2$ , 3H, Me), 4.07 (s, 2H,  $\text{CH}_2\text{O}$ ), 4.10 (dt,  $J=5.8$ , 1.5, 2H,  $\text{CH}_2\text{CH}$ ), 4.22 (q,  $J=7.2$ ,  $\text{CH}_2\text{Me}$ ), 5.26 (dq,  $J=10.3$ , 1.5, 1H,  $\text{CHH}=\text{CH}$ ), 5.33 (dd,  $J=17.1$ , 1.5,  $\text{CHH}=\text{CH}$ ), 5.93 (ddt,  $J=17.1$ , 10.3, 5.8,  $\text{CH}=\text{CHH}$ );  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  14.1, 60.8, 67.1, 72.3, 118.2, 133.6, 170.3.

**4.1.5. Ethyl 2-(cyclopent-2-enyl)acetate 35.**<sup>20</sup> Acetyl chloride (3 mL, 42.4 mmol) was added dropwise to a solution of ethanol (30 mL) at 0 °C. 2-(Cyclopent-2-enyl)acetic acid (2 g, 15.9 mmol) was added dropwise to the solution at 0 °C. The resulting mixture was allowed to warm to room temperature and was then heated at reflux for 4 h. After concentration under reduced pressure the residue was dissolved in chloroform and concentrated under reduced pressure again to give a biphasic mixture. The mixture was extracted with dichloromethane (10 mL) and the combined organic layers were dried over MgSO<sub>4</sub> and concentrated under reduced pressure. The crude product was purified by flash chromatography (4:1 petrol–ether) to give the ester as a pale yellow oil (1.6 g, 65%); IR (film):  $\nu_{\max}$  2907 (s), 1732 (s), 1614 (w), 1259 (s), 1148 (s), 1032 (s) cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  1.26 (t, *J*=7.2, 3H, CH<sub>3</sub>), 1.42–1.50 (m, 1H, CHHCHCH<sub>2</sub>), 2.07–2.16 (m, 1H, CHHCHCH<sub>2</sub>), 2.25–2.33 (m, 2H, CH<sub>2</sub>C=O), 2.33–2.42 (m, 2H, CH<sub>2</sub>CH=CH), 3.04–3.12 (m, 1H, CHCH=CH), 4.14 (q, *J*=7.2, 2H, CH<sub>2</sub>CH<sub>3</sub>), 5.65–5.68 (m, 1H, CH=CH), 5.74–5.78 (m, 1H, CH=CH); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>):  $\delta$  14.3, 29.6, 31.8, 40.5, 41.8, 60.2, 131.4, 133.7, 173.0; MS (EI) *m/z* (%): 153 (M–H, 33), 79 (75), 57 (100); HRMS: M–H, found 153.09115. C<sub>9</sub>H<sub>13</sub>O<sub>2</sub> requires 153.09101.

**4.1.6. (E)-Ethyl 3,7-dimethylocta-2,6-dienoate 38.**<sup>21</sup> Sodium hydride (60% mineral oil dispersion, 0.312 g, 7.80 mmol) was washed three times with hexane under nitrogen. The resulting solid was suspended in dry THF (10 mL) and cooled to 0 °C. A solution of triethyl phosphonoacetate (1.75 g, 7.8 mmol) in tetrahydrofuran (6 mL) was added with stirring at 0 °C, and the mixture was stirred at this temperature for further 30 min. A solution of 6-methyl-5-hepten-2-one (0.74 g, 5.9 mmol) in tetrahydrofuran (5 mL) was added and the resulting mixture was stirred at 0 °C for 1 h and then allowed to warm to room temperature and stirred for 16 h. The residue was then poured into a mixture of ether (50 mL) and a saturated aqueous ammonium chloride (20 mL). The ether layer was separated and the aqueous layer extracted with ether (2×20 mL). The combined organic layers were dried over MgSO<sub>4</sub> and concentrated under reduced pressure. The crude product (approximately 75:25 *E:Z*) was purified by column chromatography (3% <sup>t</sup>BuOMe in hexane) to give 1.03 g of a mixture of (*E*) and (*Z*) isomers as a colourless oil and 187 mg of the pure *E* isomer as a colourless oil (89% overall yield). The pure *E* isomer was used in the cyclopropanation reaction; IR (film):  $\nu_{\max}$  1643 (s), 1385 (w), 1223 (w), 1142 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  1.28 (t, *J*=7.1, 3H, CH<sub>3</sub>CH<sub>2</sub>), 1.60 (s, 3H, CH<sub>3</sub>CCH<sub>3</sub>), 1.68 (s, 3H, CH<sub>3</sub>CCH<sub>3</sub>), 2.15 (s, 3H, CH<sub>3</sub>C=CH), 2.16 (m, 4H, 2×CH<sub>2</sub>), 4.15 (q, *J*=7.1, 2H, CH<sub>2</sub>CH<sub>3</sub>), 5.03–5.1 (m, 1H, CHCOO), 5.66 (br s, 1H, Me<sub>2</sub>C=CH); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>):  $\delta$  14.3, 17.7, 18.8, 25.7, 26.0, 40.9, 59.5, 115.6, 123.0, 132.5, 159.8, 166.9; MS (EI) *m/z* (%): 196 (M<sup>+</sup>, 10), 151 (33), 123 (60), 97 (52), 83 (100); HRMS: M<sup>+</sup>, found 196.14572. C<sub>12</sub>H<sub>20</sub>O<sub>2</sub> requires 196.14632.

**4.1.7. Preparation of zinc amalgam.** Zinc dust (10.0 g, 153 mmol) was added portionwise to a vigorously stirred solution of mercury(II) chloride (2.0 g, 7.20 mmol) in concentrated hydrochloric acid (2 mL) and water (30 mL). The suspension was stirred for 10 min and then filtered and the zinc amalgam washed with water (3×20 mL), acetone

(3×20 mL), ethanol (3×20 mL) and ether (3×20 mL) and then dried under vacuum.

**4.1.8. Zinc dust for cyclopropanation reactions.** A suspension of commercially available zinc dust (5 g, 76.5 mmol) in 2% hydrochloric acid (15 mL) was stirred for 10 min and then filtered and the collected zinc dust washed with water (3×20 mL), acetone (3×20 mL), ethanol (3×20 mL) and ether (3×20 mL) and then dried under vacuum.

**4.1.9. General procedure for the cyclopropanation of alkenes using zinc amalgam.** A solution of diethoxymethylamide (2.11 mmol) in dry diethyl ether (3 mL) was added via a motorised syringe pump over 4–6 h to a vigorously stirred mixture of zinc amalgam (1.38 g, 21.1 mmol), zinc chloride (1.0 M solution in diethyl ether, 2.11 mL, 2.11 mmol), chlorotrimethylsilane (1.34 mL, 10.56 mmol) and alkene (1.06 mmol) in dry diethyl ether (5.5 mL) under nitrogen at reflux. The mixture was stirred at reflux overnight and then allowed to cool to room temperature. The reaction was quenched with saturated aqueous sodium bicarbonate solution (20 mL) and after stirring for 20 min, the mixture was filtered through Celite and the separated zinc washed with diethyl ether (20 mL) and dichloromethane (20 mL). The organic solvents were removed in vacuo and the aqueous layer was extracted with diethyl ether (3×20 mL). The combined organic extracts were washed with brine (20 mL), dried (MgSO<sub>4</sub>), filtered and concentrated in vacuo. The crude product was then purified by flash column chromatography to give the amidocyclopropane(s).

**4.1.10. General procedure for cyclopropanation of alkenes using Zn/CuCl.** A solution of diethoxymethylamide (2.12 mmol) in diethyl ether (3 mL) was added dropwise via syringe pump (0.6 mL h<sup>-1</sup>) to a vigorously stirred refluxing mixture of zinc dust (1.4 g, 21.5 mmol), copper(I) chloride (140 mg, 1.4 mmol), zinc chloride (1.0 M solution in Et<sub>2</sub>O, 1 mL, 1 mmol), alkene (1.06 mmol) and chlorotrimethylsilane (1.4 mL, 11 mmol) in diethyl ether (5 mL). The reaction mixture was refluxed overnight, then quenched by addition of saturated sodium bicarbonate solution (4 mL), filtered and washed the resulting solids with ether (10 mL). The biphasic mixture was extracted with ether (3×20 mL) and the combined organic layers washed with brine (30 mL), dried (MgSO<sub>4</sub>) and concentrated. The residue was purified by column chromatography to give the amidocyclopropane.

**4.1.11. General procedure for cyclopropanation of alkenes without TMSCl.** A solution of diethoxymethylamide (2.12 mmol) in diethyl ether (2 mL) was added dropwise via syringe pump (0.6 mL h<sup>-1</sup>) to a vigorously stirred refluxing mixture of zinc dust (1.4 g, 21.5 mmol), copper(I) chloride (140 mg, 1.4 mmol), zinc chloride (1.0 M solution in Et<sub>2</sub>O, 5.4 mL, 5.4 mmol), alkene (1.06 mmol) in diethyl ether (1 mL). The reaction mixture was refluxed overnight, then quenched by addition of saturated sodium bicarbonate solution (4 mL), filtered and washed the resulting solids with ether (10 mL). The biphasic mixture was extracted with ether (3×20 mL) and the combined organic layers washed with brine (30 mL), dried (MgSO<sub>4</sub>) and concentrated. The residue was purified by column chromatography to give the amidocyclopropane.



**4.1.12. Procedure for cyclopropanation of allyl benzene using oxazolidinone 7 and triethyl orthoformate.** Zinc chloride (1.0 M solution in Et<sub>2</sub>O, 2.7 mL, 2.70 mmol) and chlorotrimethylsilane (2.45 mL, 18.9 mmol) were added to a suspension of oxazolidinone (238 mg, 2.70 mmol) in ether (5 mL) and the solution heated at reflux for 10 min. Zinc dust (1.32 g, 20.3 mmol) and copper(I) chloride (132 mg, 1.32 mmol) were added followed by a solution of allyl benzene (165 mg, 1.39 mmol) in ether (2 mL). The reaction mixture was then heated at reflux and triethyl orthoformate (2.3 mL, 13.5 mmol) was added dropwise via syringe pump (0.25 mL h<sup>-1</sup>). After heating under reflux overnight, saturated sodium bicarbonate solution (4 mL) was added and the resulting suspension was filtered and washed the solids with ether (10 mL). The biphasic mixture was extracted with ether (3×20 mL) and the combined organic layers washed with brine (30 mL), dried (MgSO<sub>4</sub>) and concentrated. The residue was purified by column chromatography to give the amidocyclopropane **56** as a colourless oil (100 mg, 0.46 mmol, 33%).

**4.1.13. 1-(2-Benzylcyclopropyl)-2-pyrrolidinone (trans and cis) 39.** Colourless oil; IR (mixture of *trans* and *cis*, film):  $\nu_{\max}$  2992, 2958, 1688 (s), 1495, 1454, 1421 (s) cm<sup>-1</sup>; <sup>1</sup>H NMR (*trans*, 500 MHz, CDCl<sub>3</sub>):  $\delta$  0.75 (ddd, *J*=7.5, 6.1, 5.8, 1H, CHHCHN), 0.95 (ddd, *J*=9.4, 5.8, 4.1, 1H, CHHCHN), 1.28 (dtdd, *J*=9.4, 6.8, 6.1, 3.5, 1H, CHCHN), 1.86–1.93 (m, 2H, CH<sub>2</sub>CH<sub>2</sub>N), 2.32 (t, *J*=8.0, 2H, CH<sub>2</sub>CO), 2.50–2.55 (m, 2H, CHN and CHHAr), 2.70 (dd, *J*=14.7, 6.8, 1H, CHHAr), 3.16 (t, *J*=7.0, 2H, CH<sub>2</sub>N), 7.18–7.30 (m, 5H, Ar-H); <sup>13</sup>C NMR (*trans*, 125 MHz, CDCl<sub>3</sub>):  $\delta$  12.1, 17.8, 19.0, 31.6, 31.6, 38.0, 47.2, 125.9, 128.2, 140.5, 175.8. <sup>1</sup>H NMR (*cis*, 500 MHz, CDCl<sub>3</sub>):  $\delta$  0.71 (ddd, *J*=6.4, 6.0, 4.6, 1H, CHHCHN), 1.00 (ddd, *J*=8.9, 8.0, 6.0, 1H, CHHCHN), 1.34 (tddd, *J*=8.9, 7.1, 6.4, 4.9, 1H, CHCHN), 1.94–2.01 (m, 2H, CH<sub>2</sub>CH<sub>2</sub>N), 2.19 (dd, *J*=14.4, 8.9, 1H, CHHAr), 2.38–2.42 (m, 2H, CH<sub>2</sub>CO), 2.66 (ddd, *J*=8.0, 7.1, 4.6, 1H, CHN), 3.02 (dd, *J*=14.4, 4.9, 1H, CHHAr), 3.29–3.39 (m, 2H, CH<sub>2</sub>N), 7.18–7.30 (m, 5H, Ar-H); <sup>13</sup>C NMR (*cis*, 125 MHz, CDCl<sub>3</sub>):  $\delta$  10.3, 18.2, 18.5, 30.4, 31.6, 33.8, 49.1, 125.8, 128.2, 141.1, 176.9; MS (FAB) *m/z* (%): 216 (M+H, 100), 124 (63), 91 (29); HRMS: M<sup>+</sup>, found 215.13149. C<sub>14</sub>H<sub>17</sub>NO requires 215.1310.

**4.1.14. 1-(2-Phenylcyclopropyl)-2-pyrrolidinone (trans and cis) 40.** Colourless oil; IR (mixture of *trans* and *cis*, film):  $\nu_{\max}$  2980 (s), 2886 (s), 1680 (s), 1499, 1459 cm<sup>-1</sup>; <sup>1</sup>H NMR (*trans*, 500 MHz, CDCl<sub>3</sub>):  $\delta$  1.28 (dt, *J*=7.7, 6.3, 1H, CHHCHN), 1.39 (ddd, *J*=9.8, 6.3, 4.6, 1H, CHHCHN), 1.96–2.03 (m, 2H, CH<sub>2</sub>CH<sub>2</sub>N), 2.17 (ddd, *J*=9.9, 6.3, 3.6, 1H, CHCHN), 2.39 (t, *J*=8.1, 2H, CH<sub>2</sub>CO), 2.78 (ddd, *J*=7.7, 4.6, 3.6, 1H, CHN), 3.35–3.40 (m, 2H, CH<sub>2</sub>N), 7.10–7.19 (m, 3H, Ar-H), 7.22–7.28 (m, 2H, Ar-H); <sup>13</sup>C NMR (*trans*, 125 MHz, CDCl<sub>3</sub>):  $\delta$  14.7, 18.1, 22.7, 31.8, 34.9, 47.5, 126.1, 126.4, 128.4, 140.4, 175.9. <sup>1</sup>H NMR (*cis*, 500 MHz, CDCl<sub>3</sub>):  $\delta$  1.37 (ddd, *J*=9.1, 7.8, 6.8, 1H, CHHCHN), 1.45–1.53 (m, 1H, CHHCH<sub>2</sub>N), 1.56–1.65 (m, 2H, CHHCHN and CHHCH<sub>2</sub>N), 2.10–2.22 (m, 3H, CHCHN and CH<sub>2</sub>CO), 2.64 (ddd, *J*=9.5, 8.5, 4.8, 1H, CHHCHN), 2.79 (td, *J*=7.8, 4.9, 1H, CHN), 2.85 (ddd, *J*=9.5, 8.0, 6.8, 1H, CHHCHN), 7.07–7.14 (m, 3H, Ar-H), 7.17–7.21 (m, 2H, Ar-H); <sup>13</sup>C NMR (*cis*, 125 MHz, CDCl<sub>3</sub>):  $\delta$  10.7, 18.0, 21.7,

31.5, 32.4, 48.0, 126.1, 127.8, 127.9, 136.8, 176.7; MS (EI) *m/z* (%): 201 (M<sup>+</sup>, 7), 172 (21), 144 (24), 130 (69), 115 (100), 103 (72), 91 (52), 77 (74); HRMS: M<sup>+</sup>, found 201.11549. C<sub>13</sub>H<sub>15</sub>NO requires 201.11482.

**4.1.15. trans-1-(2-tert-Butylcyclopropyl)-2-pyrrolidinone 41.** Colourless oil; IR (film):  $\nu_{\max}$  2955 (s), 2868, 1694 (s), 1462, 1421 (s) cm<sup>-1</sup>; <sup>1</sup>H NMR (*trans*, 500 MHz, CDCl<sub>3</sub>):  $\delta$  0.67–0.74 (m, 2H, CH<sub>2</sub>CHN), 0.81 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>), 0.86 (ddd, *J*=9.9, 6.8, 4.1, 1H, CHCHN), 1.84–1.94 (m, 2H, CH<sub>2</sub>CH<sub>2</sub>N), 2.29 (t, *J*=8.2, 2H, CH<sub>2</sub>CO), 2.47 (dt, *J*=7.5, 4.1, 1H, CHN), 3.26 (t, *J*=7.1, 2H, CH<sub>2</sub>N); <sup>13</sup>C NMR (*trans*, 125 MHz, CDCl<sub>3</sub>):  $\delta$  8.7, 17.9, 28.1, 28.1, 29.0, 29.5, 31.8, 47.5, 175.8; MS (EI) *m/z* (%): 181 (M<sup>+</sup>, 20), 166 (10), 124 (100), 96 (29), 81 (23), 69 (14), 57 (12); HRMS: M<sup>+</sup>, found 181.146380. C<sub>11</sub>H<sub>19</sub>NO requires 181.146655.

**4.1.16. (±)-1-((2S,3S)-2,3-Dibutylcyclopropyl)pyrrolidin-2-one 42.** Colourless oil; IR (film):  $\nu_{\max}$  2954 (s), 2924 (s), 2856, 1694 (s), 1416 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  0.68–0.79 (m, 3H), 0.82 (t, *J*=7.0, 3H, Me), 0.83 (t, *J*=7.0, 3H, CH<sub>3</sub>), 1.14–1.36 (m, 10H), 1.45–1.53 (m, 1H), 1.87–1.96 (m, 2H, CH<sub>2</sub>CH<sub>2</sub>N), 2.25 (dd, *J*=6.4, 4.2, 1H, CHN), 2.32 (t, *J*=8.0, 2H, CH<sub>2</sub>CO), 3.20–3.31 (m, 2H, CH<sub>2</sub>N); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>):  $\delta$  13.9, 14.0, 18.8, 22.4, 22.5, 24.1, 25.5, 27.5, 31.0, 31.6, 31.6, 32.5, 36.6, 49.0, 176.6; MS (EI) *m/z* (%): 237 (M<sup>+</sup>, 43), 194 (21), 180 (100), 138 (15), 124 (35), 98 (53), 86 (35), 67 (13), 55 (15); HRMS: M<sup>+</sup>, found 237.2084. C<sub>15</sub>H<sub>27</sub>NO requires 237.20925.

**4.1.17. (±)-1-((1R,2R,3S)-2,3-Dibutylcyclopropyl)pyrrolidin-2-one and (±)-1-((1S,2R,3S)-2,3-dibutylcyclopropyl)pyrrolidin-2-one 43.** Colourless oil; IR (mixture of *trans* and *cis*, film):  $\nu_{\max}$  2956 (s), 2929 (s), 2857, 1699 (s), 1464, 1417 cm<sup>-1</sup>; <sup>1</sup>H NMR (*trans*, 400 MHz, CDCl<sub>3</sub>):  $\delta$  0.88 (t, *J*=7.1, 6H, 2×Me), 0.98–1.02 (m, 2H, 2×CHBu), 1.22–1.50 (m, 12H, 6×CH<sub>2</sub>), 1.98 (tt, *J*=8.1, 7.0, 2H, CH<sub>2</sub>CH<sub>2</sub>N), 2.01 (t, *J*=3.8, 1H, CHN), 2.32 (t, *J*=8.1, 2H, CH<sub>2</sub>CO), 3.25 (t, *J*=7.0, 2H, CH<sub>2</sub>N); <sup>13</sup>C NMR (*trans*, 100 MHz, CDCl<sub>3</sub>):  $\delta$  14.1, 18.0, 22.6, 23.5, 23.5, 26.8, 31.8, 37.8, 47.4, 175.6; <sup>1</sup>H NMR (*cis*, 400 MHz, CDCl<sub>3</sub>):  $\delta$  0.88 (t, *J*=7.2, 6H, 2×Me), 0.91–0.98 (m, 2H, 2×CHBu), 1.16–1.51 (m, 12H, 6×CH<sub>2</sub>), 1.98 (tt, *J*=8.2, 7.7, 2H, CH<sub>2</sub>CH<sub>2</sub>N), 2.31 (t, *J*=8.2, 2H, CH<sub>2</sub>CO), 2.38 (t, *J*=7.7, 1H, CHN), 3.25 (t, *J*=7.0, 2H, CH<sub>2</sub>N); <sup>13</sup>C NMR (*cis*, 100 MHz, CDCl<sub>3</sub>):  $\delta$  14.1, 18.9, 19.8, 22.9, 23.4, 31.0, 32.4, 33.4, 48.8, 178.5; MS (EI) *m/z* (%): 238 (M+H, 100), 194 (25), 180 (95), 138 (13), 124 (43), 98 (73), 86 (43), 67 (10), 55 (13), 41 (34); HRMS: M<sup>+</sup>, found 237.20916. C<sub>15</sub>H<sub>27</sub>NO requires 237.20925.

**4.1.18. 1-Bicyclo[4.1.0]hept-7-yl-2-pyrrolidinone (exo and endo) 44.** Colourless oil; IR (mixture of *exo* and *endo*, film):  $\nu_{\max}$  2927 (s), 2853 (s), 1682 (s), 1418 (s) cm<sup>-1</sup>; <sup>1</sup>H NMR (*exo*, 500 MHz, C<sub>6</sub>D<sub>6</sub>):  $\delta$  0.93–1.00 (m, 2H), 1.03–1.11 (m, 4H), 1.21 (tt, *J*=8.0, 7.0, 2H, CH<sub>2</sub>CH<sub>2</sub>N), 1.65–1.79 (m, 4H), 1.97 (t, *J*=8.0, 2H, CH<sub>2</sub>CO), 2.22 (t, *J*=3.7, 1H, CHN), 2.57 (t, *J*=7.0, 2H, CH<sub>2</sub>N); <sup>13</sup>C NMR (*exo*, 125 MHz, C<sub>6</sub>D<sub>6</sub>):  $\delta$  17.2, 18.1, 21.6, 22.7, 31.6, 36.9, 46.4, 174.4. <sup>1</sup>H NMR (*endo*, 500 MHz, C<sub>6</sub>D<sub>6</sub>):  $\delta$  0.87–0.92 (m, 2H, 2×CHCHN),

0.93–1.13 (m, 4H), 1.29 (tt,  $J=7.9$ , 6.9, 2H,  $\text{CH}_2\text{CH}_2\text{N}$ ), 1.65–1.79 (m, 4H), 1.93 (t,  $J=7.9$ , 2H,  $\text{CH}_2\text{CO}$ ), 2.04 (t,  $J=7.7$ , 1H, CHN), 2.79 (t,  $J=6.9$ , 2H,  $\text{CH}_2\text{N}$ );  $^{13}\text{C}$  NMR (*endo*, 125 MHz,  $\text{C}_6\text{D}_6$ ):  $\delta$  13.0, 18.9, 20.2, 22.5, 30.9, 34.0, 48.0, 176.7; MS (EI)  $m/z$  (%): 179 ( $\text{M}^+$ , 100), 150 (32), 136 (15), 124 (20), 108 (10), 98 (32), 94 (30), 79 (19), 72 (30), 59 (57), 55 (48); HRMS:  $\text{M}^+$ , found 179.13102.  $\text{C}_{11}\text{H}_{17}\text{NO}$  requires 179.1310.

**4.1.19. 1-(1-Methylbicyclo[4.1.0]hept-7-yl)-2-pyrrolidinone (*exo* and *endo*) 45.** Colourless oil; IR (mixture of *exo* and *endo*, film):  $\nu_{\text{max}}$  2929 (s), 2861, 1693 (s), 1492 (w), 1412  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (mixture of *exo* and *endo*, 500 MHz,  $\text{C}_6\text{D}_6$ ):  $\delta$  0.73 (td,  $J=7.9$ , 2.6, 1H, CHCHN), 0.90 (ddd,  $J=7.5$ , 4.1, 1.7, 1H, CHCHN), 0.96–1.22 (m, 14H), 1.27–1.35 (m, 4H,  $\text{CH}_2\text{CH}_2\text{N}$ ), 1.47–1.66 (m, 4H), 1.75–1.90 (m, 5H), 1.91–1.96 (m, 2H), 1.98–2.03 (m, 2H), 2.09 (d,  $J=4.2$ , 1H, CHN), 2.66 (dt,  $J=9.3$ , 7.0, 1H), 2.68 (dt,  $J=9.3$ , 7.0, 1H), 2.78 (dt,  $J=9.3$ , 7.0, 1H), 2.80 (dt,  $J=9.3$ , 6.3, 1H);  $^{13}\text{C}$  NMR (mixture of *exo* and *endo*, 125 MHz,  $\text{C}_6\text{D}_6$ ):  $\delta$  18.2, 18.6, 19.0, 20.4, 21.6, 21.7, 21.7, 21.9, 22.1, 22.3, 22.4, 23.2, 23.5, 27.8, 28.0, 30.5, 31.0, 31.4, 41.2, 41.4, 47.9, 48.1, 175.2, 176.6; MS (EI)  $m/z$  (%): 193 ( $\text{M}^+$ , 67), 178 (45), 164 (20), 150 (15), 124 (10), 108 (83), 98 (53), 93 (55), 86 (100), 79 (18), 55 (14). HRMS:  $\text{M}^+$ , found 193.14610.  $\text{C}_{12}\text{H}_{19}\text{NO}$  requires 193.14655.

**4.1.20. 2-Ethylhexyl-[2-(2-oxopyrrolidin-1-yl)-cyclopropyl]carboxylate (*trans* and *cis*) 46.** Colourless oil; IR (diastereomeric mixture of *trans* and *cis*, film):  $\nu_{\text{max}}$  2961 (s), 2934 (s), 2875, 2862, 1741 (s), 1698 (s), 1460 (s), 1420 (s)  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (diastereomeric mixture of *trans*-cyclopropanes, 500 MHz,  $\text{CDCl}_3$ ):  $\delta$  0.74 (t,  $J=7.2$ , 12H,  $4\times\text{CH}_3$ ), 1.05–1.21 (m, 10H), 1.22 (td,  $J=7.6$ , 5.5, 2H), 1.26–1.51 (m, 8H), 1.80–1.93 (m, 4H,  $2\times\text{CH}_2\text{CH}_2\text{N}$ ), 2.10 (tt,  $J=8.8$ , 5.5, 2H,  $2\times\text{OCOCH}$ ), 2.22 (t,  $J=8.3$ , 4H,  $2\times\text{CH}_2\text{CO}$ ), 2.57 (ddd,  $J=7.4$ , 5.3, 1.8, 2H,  $2\times\text{CHN}$ ), 3.26–3.38 (m, 4H,  $2\times\text{CH}_2\text{N}$ ), 3.97 (ddd,  $J=7.4$ , 4.4, 1.8, 2H,  $2\times\text{CHOCO}$ );  $^{13}\text{C}$  NMR (diastereomeric mixture of *trans*-cyclopropanes, 125 MHz,  $\text{CDCl}_3$ ):  $\delta$  11.5, 13.6, 17.8, 22.3, 25.0, 29.2, 31.1, 31.3, 46.6, 47.0, 51.7, 175.8, 176.2, 176.7.  $^1\text{H}$  NMR (diastereomeric mixture of *cis* cyclopropanes, 300 MHz,  $\text{CDCl}_3$ ):  $\delta$  0.83 (t,  $J=7.3$ , 12H,  $4\times\text{CH}_3$ ), 1.13–1.57 (m, 20H), 1.89–2.01 (m, 4H,  $2\times\text{CH}_2\text{CH}_2\text{N}$ ), 2.19 (tt,  $J=8.2$ , 5.6, 2H,  $2\times\text{OCOCH}$ ), 2.34 (t,  $J=8.1$ , 4H,  $2\times\text{CH}_2\text{CO}$ ), 2.65–2.70 (m, 2H,  $2\times\text{CHN}$ ), 3.26–3.43 (m, 4H,  $2\times\text{CH}_2\text{N}$ ), 4.14 (td,  $J=7.1$ , 4.1, 1H,  $2\times\text{CHOCO}$ ), 4.15 (td,  $J=7.1$ , 4.1, 1H,  $2\times\text{CHOCO}$ );  $^{13}\text{C}$  NMR (diastereomeric mixture of *cis* cyclopropanes, 125 MHz,  $\text{CDCl}_3$ ):  $\delta$  11.2, 11.6, 13.8, 18.3, 22.5, 25.0, 25.3, 28.7, 29.4, 31.3, 31.5, 31.6, 47.0, 48.1, 49.7, 176.3, 176.5; MS (EI)  $m/z$  (%): 268 ( $\text{M}+\text{H}$ , 49), 140 (99), 124 (32), 112 (87), 99 (28), 84 (11), 69 (42), 57 (100), 41 (73); HRMS:  $\text{M}+\text{H}$ , found 268.19116.  $\text{C}_{15}\text{H}_{26}\text{NO}_3$  requires 268.19124.

**4.1.21. 2-Ethylhexyl-[1-methyl-2-(2-oxopyrrolidin-1-yl)-cyclopropyl]carboxylate (*trans* and *cis*) 47.** Colourless oil; IR (diastereomeric mixture of *trans* and *cis*, film):  $\nu_{\text{max}}$  2975 (s), 2931 (s), 2865, 1700 (s), 1459 (w), 1419 (w)  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (diastereomeric mixture of *trans* and *cis*, 500 MHz,  $\text{CDCl}_3$ ):  $\delta$  0.85 (t,  $J=7.0$ , 24H,  $8\times\text{CH}_3$ ), 1.04 (t,  $J=6.8$ , 2H), 1.18–1.35 (m, 46H), 1.49–1.56 (m,

4H,  $4\times\text{OCH}_2\text{CH}$ ), 1.63 (dd,  $J=8.7$ , 5.8, 2H), 1.67–1.71 (m, 2H), 1.89–2.03 (m, 8H,  $4\times\text{CH}_2\text{CH}_2\text{N}$ ), 2.25–2.31 (m, 4H,  $2\times\text{CH}_2$ ), 2.37 (t,  $J=8.4$ , 4H,  $2\times\text{CH}_2$ ), 2.69 (t,  $J=6.8$ , 2H,  $2\times\text{CHN}$ ), 2.99 (dd,  $J=8.5$ , 5.7, 2H,  $2\times\text{CHN}$ ), 3.20–3.36 (m, 6H), 3.49 (dt,  $J=8.9$ , 7.5, 2H), 3.85–3.98 (m, 8H,  $4\times\text{OCH}_2\text{CH}$ );  $^{13}\text{C}$  NMR (diastereomeric mixture of *trans* and *cis*, 125 MHz,  $\text{CDCl}_3$ ):  $\delta$  10.9, 11.0, 13.3, 18.3, 18.4, 19.2, 20.5, 20.8, 22.9, 23.7, 23.8, 24.3, 26.2, 29.3, 30.3, 30.4, 38.6, 38.7, 40.4, 48.0, 48.9, 67.1, 67.2, 67.3, 172.2, 174.0, 176.4, 176.5; MS (EI)  $m/z$  (%): 296 ( $\text{M}+\text{H}$ , 100), 183 (60), 165 (65), 138 (85), 98 (64), 71 (14), 57 (27), 41 (49); HRMS:  $\text{M}+\text{H}$ , found 296.22254.  $\text{C}_{17}\text{H}_{30}\text{NO}_3$  requires 296.22234.

**4.1.22. [2-(2-Oxopyrrolidin-1-yl)-cyclopropyl]benzoate (*trans* and *cis*) 48.** Colourless oil; IR (mixture of *trans* and *cis*, film):  $\nu_{\text{max}}$  2961, 1726 (s), 1689 (s), 1615 (w), 1452, 1420 (s)  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (*trans*, 500 MHz,  $\text{CDCl}_3$ ):  $\delta$  1.40–1.43 (m, 2H), 1.89–1.98 (m, 2H,  $\text{CH}_2\text{CH}_2\text{N}$ ), 2.36 (t,  $J=8.4$ , 2H,  $\text{CH}_2\text{CO}$ ), 2.80 (ddd,  $J=7.8$ , 7.0, 5.4, 1H, CHN), 3.33–3.43 (m, 2H,  $\text{CH}_2\text{N}$ ), 4.44 (q,  $J=5.4$ , 1H, CHOCO), 7.38–7.42 (m, 2H, Ar-H), 7.51–7.56 (m, 1H, Ar-H), 7.90–7.94 (m, 2H, Ar-H);  $^{13}\text{C}$  NMR (*trans*, 125 MHz,  $\text{CDCl}_3$ ):  $\delta$  11.2, 18.5, 29.0, 31.5, 48.2, 50.6, 128.4, 129.3, 129.3, 133.2, 166.8, 176.7.  $^1\text{H}$  NMR (*cis*, 500 MHz,  $\text{CDCl}_3$ ):  $\delta$  1.44–1.48 (m, 2H,  $\text{CH}_2\text{CH}_2\text{N}$ ), 1.95–2.07 (m, 2H,  $\text{CH}_2\text{CH}_2\text{N}$ ), 2.37 (t,  $J=8.4$ , 2H,  $\text{CH}_2\text{CO}$ ), 2.85 (ddd,  $J=9.0$ , 6.6, 1.8, 1H, CHN), 3.45–3.53 (m, 2H,  $\text{CH}_2\text{N}$ ), 4.33 (ddd,  $J=6.6$ , 5.4, 1.8, 1H, CHO), 7.38–7.42 (m, 2H, Ar-H), 7.51–7.56 (m, 1H, Ar-H), 7.90–7.94 (m, 2H, Ar-H);  $^{13}\text{C}$  NMR (*cis*, 125 MHz,  $\text{CDCl}_3$ ):  $\delta$  14.0, 18.5, 31.4, 31.6, 47.4, 52.6, 128.4, 129.3, 129.6, 133.3, 167.1, 176.2; MS (EI)  $m/z$  (%): 245 ( $\text{M}^+$ , 74), 216 (24), 162 (61), 154 (22), 141 (86), 124 (100), 114 (100), 106 (89), 94 (87), 84 (90), 77 (86); HRMS:  $\text{M}^+$ , found 245.10578.  $\text{C}_{14}\text{H}_{15}\text{NO}_3$  requires 245.10519.

**4.1.23. 1-(2-Trimethylsilylcyclopropyl)-2-pyrrolidinone 49.** Colourless oil; IR (film):  $\nu_{\text{max}}$  2954 (s), 2894, 1694 (s), 1419 (s)  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (*trans*, 500 MHz,  $\text{CDCl}_3$ ):  $\delta$  -0.12 (ddd,  $J=11.3$ , 8.2, 5.3, 1H, CHSi), -0.06 (s, 9H,  $\text{Si}(\text{CH}_3)_3$ ), 0.63 (ddd,  $J=8.2$ , 6.5, 4.8, 1H, CHHCHN), 0.89 (ddd,  $J=11.3$ , 4.8, 3.6, 1H, CHHCHN), 1.84–1.94 (m, 2H,  $\text{CH}_2\text{CH}_2\text{N}$ ), 2.31 (t,  $J=8.0$ , 2H,  $\text{CH}_2\text{CO}$ ), 2.50 (ddd,  $J=6.5$ , 5.3, 3.6, 1H, CHN), 3.18–3.22 (m, 2H,  $\text{CH}_2\text{N}$ );  $^{13}\text{C}$  NMR (*trans*, 125 MHz,  $\text{CDCl}_3$ ):  $\delta$  -2.6, 4.2, 8.6, 18.0, 29.1, 31.2, 47.2, 175.8; MS (EI)  $m/z$  (%): 197 ( $\text{M}^+$ , 40), 182 (66), 168 (36), 154 (27), 142 (66), 124 (11), 73 (100), 59 (22); HRMS:  $\text{M}^+$ , found 197.12332.  $\text{C}_{10}\text{H}_{19}\text{NOSi}$  requires 197.12355.

**4.1.24. 1-[2-(Benzylidimethylsilyl)-cyclopropyl]-2-pyrrolidinone 50.** Colourless oil; IR (film):  $\nu_{\text{max}}$  2953 (m), 2891 (w), 1689 (s), 1493 (m), 1419 (m)  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  -0.10 (s, 3H, SiMe), -0.08 (ddd,  $J=11.3$ , 8.2, 5.3, 1H, CHSi), -0.05 (s, 3H, SiMe), 0.64 (ddd,  $J=8.2$ , 6.7, 5.0, 1H, CHHCHN), 0.92 (ddd,  $J=11.3$ , 5.0, 3.7, 1H, CHHCHN), 1.87–1.95 (m, 2H,  $\text{CH}_2\text{CH}_2\text{N}$ ), 2.13 (s, 2H,  $\text{CH}_2\text{Ph}$ ), 2.34 (t,  $J=8.0$ , 2H,  $\text{CH}_2\text{CO}$ ), 2.61 (ddd,  $J=6.7$ , 5.3, 3.7, 1H, CHN), 3.16 (t,  $J=7.0$ , 2H,  $\text{CH}_2\text{N}$ ), 6.99–7.06 (m, 3H, Ar-H), 7.15–7.20 (m, 2H, Ar-H);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ ):  $\delta$  -4.8, -4.6, 2.7, 8.4, 18.0, 25.2, 29.1, 31.9, 47.0, 124.0, 128.1,

128.2, 139.8, 175.9; MS (EI)  $m/z$  (%): 273 ( $M^+$ , 62), 258 (24), 218 (24), 182 (92), 149 (100), 121 (86), 97 (31), 91 (23); HRMS:  $M^+$ , found 273.15083.  $C_{16}H_{23}NOSi$  requires 273.15488.

**4.1.25. *trans*-2-(2-Oxopyrrolidin-1-yl)cyclopropylmethylbenzoate 51.** Colourless oil; IR (film):  $\nu_{max}$  2924, 1786 (s), 1717 (s), 1682 (s)  $cm^{-1}$ ;  $^1H$  NMR (*trans*, 300 MHz,  $CDCl_3$ ):  $\delta$  0.94 (m, 1H,  $CHHCHN$ ), 1.10 (m, 1H,  $CHHCHN$ ), 1.56 (m, 1H,  $CHCH_2O$ ), 1.97 (m, 2H,  $CH_2CH_2N$ ), 2.37 (t,  $J=8.0$ , 2H,  $CH_2CON$ ), 2.67 (dt,  $J=7.6$ , 3.7, 1H, CHN), 3.31 (t,  $J=7.0$ , 2H,  $CH_2N$ ), 4.17 (dd,  $J=11.6$ , 7.6, 1H,  $CHHO_2Ph$ ), 4.32 (dd,  $J=11.6$ , 6.6, 1H,  $CHHO_2CPh$ ), 7.44 (dd,  $J=7.5$ , 7.9, 2H, *meta*-Ar), 7.56 (t,  $J=7.5$ , 1H, *para*-Ar), 8.06 (d,  $J=7.9$ , 2H, *ortho*-Ar);  $^{13}C$  NMR (*trans*, 75 MHz,  $CDCl_3$ ): 10.6, 17.3, 18.0, 30.6, 31.7, 47.5, 66.6, 128.4, 129.6, 130.2, 133.0, 166.6, 176.0; MS (CI+)  $m/z$  (%): 260 (M+H, 70), 138 (100); HRMS: M+H, found 260.12885.  $C_{15}H_{18}NO_3$  requires 260.12866.

**4.1.26. *endo*-1-(1,1a,6,6a-Tetrahydro-cyclopropainden-1-yl)-pyrrolidin-2-one 52.** White needles; mp 53–54 °C ( $CH_2Cl_2$ –petrol); IR (film):  $\nu_{max}$  3036 (s), 2965 (s), 2912 (s), 2872 (s), 1693 (s)  $cm^{-1}$ ;  $^1H$  NMR (*exo*, 300 MHz,  $CDCl_3$ ):  $\delta$  1.12–1.26 (m, 1H,  $CHHCH_2N$ ), 1.62 (dddd,  $J=11.6$ , 8.8, 7.9, 4.7, 3.5, 1H,  $CHHCH_2N$ ), 2.05–2.15 (m, 2H,  $CH_2CO$ ), 2.25–2.33 (m, 1H,  $CH_2CH$ ), 2.45 (ddd,  $J=9.4$ , 8.6, 3.5, 1H,  $CHHN$ ), 2.68 (dd,  $J=7.1$ , 6.5, 1H, ArCH), 2.77 (br t,  $J=7.1$ , 1H, CHN), 2.99 (dt,  $J=9.4$ , 7.9, 1H,  $CHHN$ ), 3.05–3.12 (m, 2H, Ar $CH_2$ ), 7.03–7.10 (m, 3H, Ar-H), 7.29–7.34 (m, 1H, Ar-H);  $^{13}C$  NMR (*endo*, 125 MHz,  $CDCl_3$ ): 18.8, 23.2, 28.6, 31.1, 32.2, 34.8, 47.4, 123.7, 124.9, 125.7, 126.2, 139.7, 144.1, 177.5. MS (CI+)  $m/z$  (%): 214 (M+H, 100), 129 (60), 98 (42), 86 (40); HRMS: M+H, found 214.12298.  $C_{14}H_{16}NO$  requires 214.12318.

**4.1.27. 1-(1a,2,3,7b-Tetrahydro-1H-cyclopropa[a]naphthalen-1-yl)-pyrrolidin-2-one 53 (*endo* and *exo*).** Colourless oil; IR (film):  $\nu_{max}$  2926, 2856, 1693 (s)  $cm^{-1}$ ;  $^1H$  NMR (*trans*, 500 MHz,  $CDCl_3$ ): (mixture of isomers)  $\delta$  1.40–3.05 (m, 12H,  $CH_2$  and CH), 3.25–3.42 (m, 1H), 6.90–7.15 (m, 3H, Ar-H), 7.20–7.35 (m, 1H, Ar-H);  $^{13}C$  NMR (mixture of isomers, 125 MHz,  $CDCl_3$ ): 17.9, 18.0, 18.1, 18.6, 18.9, 19.5, 21.1, 22.3, 26.0, 27.4, 31.0, 31.7, 34.0, 37.3, 47.3, 47.7, 125.5, 125.8, 125.9, 126.1, 128.5, 128.6, 128.7, 130.3, 133.2, 133.9, 135.4, 135.5, 175.7, 177.7; MS (EI)  $m/z$  (%): 227 ( $M^+$ , 10), 142 (100), 128 (25), 115 (20), 99 (62), 86 (45); HRMS:  $M^+$ , found 227.13122.  $C_{15}H_{17}NO$  requires 227.13101.

**4.1.28. Ethyl 2-*cis*-((2-(2-oxopyrrolidin-1-yl)cyclopropyl)methoxy)acetate 54.** Colourless oil; IR (film):  $\nu_{max}$  2980, 1751 (s), 1690 (s)  $cm^{-1}$ ;  $^1H$  NMR (*cis*, 300 MHz,  $CDCl_3$ ):  $\delta$  0.92 (td,  $J=6.3$ , 4.7, 1H,  $CHHCHN$ ), 1.08 (ddd,  $J=9.0$ , 7.7, 6.3, 1H,  $CHHCHN$ ), 1.27 (t,  $J=7.1$ , 3H, Me), 1.35–1.47 (m, 1H,  $CHCHN$ ), 1.91–2.03 (m, 2H,  $CH_2CH_2N$ ), 2.33–2.41 (m, 2H,  $CH_2CO$ ), 2.54–2.62 (ddd,  $J=7.7$ , 6.8, 4.7, 1H, CHN), 3.31 (dt,  $J=14.7$ , 7.0, 1H,  $CHHN$ ), 3.37 (dd,  $J=10.0$ , 6.8, 1H,  $CHHOR$ ), 3.44–3.57 (m, 1H,  $CHHN$ ), 3.62 (dd,  $J=10.0$ , 7.5, 1H,  $CHHOR$ ), 4.05–4.25 (m, 4H,  $CH_2Me$  and  $CH_2CO_2Et$ );  $^{13}C$  NMR (*cis*, 125 MHz,

$CDCl_3$ ): 8.6, 13.9, 16.6, 18.1, 29.5, 31.4, 48.8, 60.5, 67.6, 70.2, 170.0, 176.9; MS (CI+)  $m/z$  (%): 242 (M+H, 71), 214 (39), 195 (31), 138 (100); HRMS: M+H, found 242.13896.  $C_{12}H_{20}NO_4$  requires 242.13923.

**4.1.29. 1-(2,2,3,3-Tetramethylcyclopropyl)pyrrolidin-2-one 55.** Colourless oil; IR (film):  $\nu_{max}$  2924 (s), 2870 (s), 1682 (s)  $cm^{-1}$ ;  $^1H$  NMR (400 MHz,  $CDCl_3$ ):  $\delta$  0.99 (s, 6H, 2×Me), 1.08 (s, 6H, 2×Me), 1.72 (s, 1H, CHN), 1.94 (m, 2H,  $CH_2$ ), 2.28 (t,  $J=8.0$ , 2H,  $CH_2CO$ ), 3.29 (t,  $J=6.9$ , 2H,  $CH_2N$ );  $^{13}C$  NMR (100 MHz,  $CDCl_3$ ): 17.6, 18.8, 22.0, 23.2, 31.0, 46.1, 48.6, 177.9; MS (EI)  $m/z$  (%): 182 (M+H, 100), 166 (15), 154 (15); HRMS: M+H, found 182.15411.  $C_{11}H_{21}NO$  requires 182.15448.

**4.1.30. 3-(2-Benzylcyclopropyl)-2-oxazolidinone 56.** Colourless oil; IR (mixture of *trans* and *cis*, film):  $\nu_{max}$  3003 (w), 2915 (w), 1742 (s), 1604 (w), 1482 (w), 1419 (w)  $cm^{-1}$ ;  $^1H$  NMR (*trans*, 500 MHz,  $CDCl_3$ ):  $\delta$  0.82 (dt,  $J=7.1$ , 6.1, 1H,  $CHHCHN$ ), 1.03 (ddd,  $J=9.5$ , 6.1, 3.5, 1H,  $CHHCHN$ ), 1.36 (dtdd,  $J=9.5$ , 6.9, 6.1, 3.5, 1H,  $CHCHN$ ), 2.40 (dt,  $J=7.1$ , 3.5, 1H, CHN), 2.59 (dd,  $J=14.5$ , 6.9, 1H,  $CHHPh$ ), 2.72 (dd,  $J=14.5$ , 6.9, 1H,  $CHHPh$ ), 3.38–3.42 (m, 2H,  $CH_2N$ ), 4.19–4.25 (m, 2H,  $CH_2O$ ), 7.20–7.32 (m, 5H, Ar-H);  $^{13}C$  NMR (*trans*, 125 MHz,  $CDCl_3$ ):  $\delta$  13.0, 20.3, 32.1, 37.8, 45.7, 61.8, 126.2, 128.2, 128.3, 140.5, 158.4.  $^1H$  NMR (*cis*, 500 MHz,  $CDCl_3$ ):  $\delta$  0.78 (td,  $J=6.3$ , 4.2, 1H,  $CHHCHN$ ), 1.05–1.15 (m, 2H,  $CHHCHN$  and  $CHCHN$ ), 2.44 (dd,  $J=15.4$ , 9.2, 1H,  $CHHPh$ ), 2.65 (ddd,  $J=7.7$ , 6.9, 4.2, 1H, CHN), 3.11 (dd,  $J=15.4$ , 5.1, 1H,  $CHHPh$ ), 3.51–3.57 (m, 2H,  $CH_2N$ ), 4.28–4.33 (m, 2H,  $CH_2O$ ), 7.20–7.32 (m, 5H, Ar-H);  $^{13}C$  NMR (*cis*, 100 MHz,  $CDCl_3$ ):  $\delta$  11.1, 18.7, 31.0, 33.7, 46.9, 62.0, 126.0, 128.2, 141.0, 159.7; MS (CI+)  $m/z$  (%): 218 (M+H, 17), 126 (100), 115 (11), 104 (15), 91 (22), 82 (12), 77 (7), 65 (8), 54 (9); HRMS: M+H, found 218.11777.  $C_{13}H_{16}NO_2$  requires 218.11809.

**4.1.31. 3-(2-*tert*-Butylcyclopropyl)-2-oxazolidinone 57.** Pale yellow oil; IR (film):  $\nu_{max}$  2958, 2869 (s), 1755 (s), 1482 (w), 1423  $cm^{-1}$ ;  $^1H$  NMR (*trans*, 500 MHz,  $CDCl_3$ ):  $\delta$  0.75 (td,  $J=7.3$ , 5.9, 1H,  $CHHCHN$ ), 0.80 (ddd,  $J=9.8$ , 5.9, 3.7, 1H,  $CHHCHN$ ), 0.85 (s, 9H, 3×Me), 0.95 (ddd,  $J=9.8$ , 7.3, 3.7, 1H,  $CHCHN$ ), 2.35 (dt,  $J=7.3$ , 3.7, 1H, CHN), 3.45–3.50 (m, 2H,  $CH_2N$ ), 4.22 (m, 2H,  $CH_2O$ );  $^{13}C$  NMR (125 MHz,  $CDCl_3$ ):  $\delta$  9.4, 28.2, 28.7, 29.0, 30.6, 45.8, 61.6, 158.4; MS (EI)  $m/z$  (%): 183 ( $M^+$ , 7), 168 (6), 127 (100), 114 (31), 82 (18), 70 (31), 55 (43), 49 (12), 42 (60); HRMS: M+H, found 184.13305.  $C_{10}H_{18}NO_2$  requires 184.13321.

**4.1.32. ( $\pm$ )-Ethyl 2-((1*R*,2*S*,5*S*,6*R*)-6-(2-oxooxazolidin-3-yl)bicyclo[3.1.0]hexan-2-yl)acetate 58a and ( $\pm$ )-ethyl 2-((1*R*,2*R*,5*S*,6*R*)-6-(2-oxooxazolidin-3-yl)bicyclo[3.1.0]hexan-2-yl)acetate 58b.** Pale yellow oil; IR (mixture of **58a** and **58b**, film):  $\nu_{max}$  2954, 1732 (s), 1417 (s)  $cm^{-1}$ ;  $^1H$  NMR (major isomer **58a**, 500 MHz,  $CDCl_3$ ):  $\delta$  1.20 (t,  $J=7.2$ , 3H,  $CH_3$ ), 1.28–1.33 (m, 1H,  $CHHCHCH_2$ ), 1.35–1.45 (m, 1H,  $CHHCHCH_2$ ), 1.45–1.49 (m, 1H,  $CHCHN$ ), 1.69–1.72 (m, 1H,  $CHCHN$ ), 1.78–1.84 (m, 1H,  $CHHCHCHN$ ), 1.84–1.91 (m, 1H,  $CHHCHCHN$ ), 2.20 (dd,  $J=15.1$ , 8.2, 1H,  $CHHCOO$ ), 2.28 (t,  $J=1.9$ , 1H, CHN), 2.32 (dd,  $J=15.1$ , 7.1, 1H,  $CHHCOO$ ), 2.62 (br q,  $J=7.5$ , 1H,  $CHCH_2CO$ ),

3.47–3.51 (m, 2H, CH<sub>2</sub>N), 4.14 (q, *J*=7.2, 2H, CH<sub>2</sub>CH<sub>3</sub>), 4.22–4.27 (m, 2H, CH<sub>2</sub>OCON); <sup>13</sup>C NMR (major isomer **58a**, 125 MHz, CDCl<sub>3</sub>): δ 14.2, 24.7, 24.8, 27.0, 29.7, 33.4, 36.5, 39.8, 45.7, 60.3, 61.8, 158.3, 172.5. <sup>1</sup>H NMR (minor isomer **58b**, 500 MHz, CDCl<sub>3</sub>): δ 0.68–0.77 (m, 1H, CHHCHCH<sub>2</sub>), 1.26 (t, *J*=7.1, 3H, CH<sub>3</sub>), 1.60–1.65 (m, 1H, CHCHN), 1.69–1.73 (m, 1H, CHCHN), 1.73–1.79 (m, 1H, CHHCHCH<sub>2</sub>), 1.79–1.88 (m, 1H, CHHCHCHN), 1.95 (dd, *J*=12.9, 8.1, 1H, CHHCHCHN), 2.28 (br t, *J*=1.9, 1H, CHN), 2.40 (dd, *J*=15.2, 7.1, 1H, CHHCOO), 2.46 (dd, *J*=15.2, 7.6, 1H, CHHCOO), 2.56–2.65 (m, 1H, CHCH<sub>2</sub>CO), 3.43–3.51 (m, 2H, CH<sub>2</sub>N), 4.14 (q, *J*=7.1, 2H, CH<sub>2</sub>CH<sub>3</sub>), 4.19–4.28 (m, 2H, CH<sub>2</sub>OCON); <sup>13</sup>C NMR (minor isomer **58b**, 125 MHz, CDCl<sub>3</sub>): δ 14.3, 25.5, 27.0, 27.6, 28.9, 30.8, 36.6, 37.8, 45.7, 60.3, 61.8, 158.4, 173.0; MS (CI+) *m/z* (%): 254 (M+H, 100), 208 (95), 166 (60), 88 (14); HRMS: M+H, found 254.13872, C<sub>13</sub>H<sub>20</sub>O<sub>4</sub>N requires 254.13923.

**4.1.33. Methyl 3-(1-chloro-2-(2-oxooxazolidin-3-yl)cyclopropyl)-2,2-dimethylpropanoate 59.**<sup>22</sup> White solid; mp 46–49 °C (petrol); IR (mixture of *trans* and *cis*, film):  $\nu_{\max}$  1634 (s), 1427 (w) cm<sup>-1</sup>; <sup>1</sup>H NMR (*trans*, 500 MHz, CDCl<sub>3</sub>): δ 1.28 (s, 3H, CH<sub>3</sub>CCH<sub>3</sub>), 1.29 (s, 3H, CH<sub>3</sub>CCH<sub>3</sub>), 1.36 (dd, *J*=9.0, 7.9, 1H, CHHCHN), 1.59 (ddd, *J*=7.9, 5.5, 1.0, 1H, CHHCHN), 2.01 (d, *J*=15.2, 1H, CHHCCHN), 2.11 (dd, *J*=15.2, 1.0, 1H, CHHCCHN), 2.51 (dd, *J*=9.0, 5.5, 1H, CHN), 3.56–3.64 (m, 1H, CHHN), 3.68 (s, 3H, CH<sub>3</sub>O), 3.74–3.80 (m, 1H, CHHN), 4.25–4.37 (m, 2H, CH<sub>2</sub>OCO); <sup>13</sup>C NMR (*cis*, 125 MHz, CDCl<sub>3</sub>): δ 22.0, 25.8, 25.8, 36.7, 42.2, 44.5, 45.6, 48.5, 51.9, 61.9, 158.5, 177.1; MS (CI+) *m/z* (%): 276 (M+H, 14), 244 (28), 216 (100), 180 (16); HRMS: M+H, found 276.09988, C<sub>12</sub>H<sub>19</sub>O<sub>4</sub>NCl requires 276.10025.

**4.1.34. *trans*-8-endo-(2-Oxooxazolidin-3-yl)-1,4,4-trimethyl-tricyclo[5.1.0.0]octane 60.** White solid; mp 60–64 °C (petrol); [ $\alpha$ ]<sub>D</sub><sup>20</sup> –27.1 (c 1.0, CHCl<sub>3</sub>); IR (mixture, film):  $\nu_{\max}$  2864 (w), 1755, 1634, 1404 cm<sup>-1</sup>; <sup>1</sup>H NMR (*endo*, 500 MHz, CDCl<sub>3</sub>): δ 0.37 (td, *J*=9.4, 3.2, 1H, CHCMe<sub>2</sub>), 0.43 (td, *J*=9.4, 3.2, 1H, CHCMe<sub>2</sub>), 0.77 (s, 3H, CH<sub>3</sub>CCHN), 0.82 (m, 1H, CHCHN), 0.98 (s, 3H, CH<sub>3</sub>CCH<sub>3</sub>), 1.02 (s, 3H, CH<sub>3</sub>CCH<sub>3</sub>), 1.30 (dd, *J*=15.7, 3.2, 1H, CHHCCH<sub>3</sub>), 1.63 (ddd, *J*=15.7, 5.8, 3.2, 1H, CHHCHCHN), 2.08 (d, *J*=7.7, 1H, CHN), 2.27 (dd, *J*=15.7, 9.4, 1H, CHHCCH<sub>3</sub>), 2.28 (dd, *J*=15.7, 9.4, 1H, CHHCHCHN), 3.63 (t, *J*=7.8, 2H, CH<sub>2</sub>N), 4.24–4.28 (m, 2H, CH<sub>2</sub>O); <sup>13</sup>C NMR (*cis*, 125 MHz, CDCl<sub>3</sub>): δ 13.9, 15.1, 16.1, 16.9, 17.1, 17.7, 20.3, 21.3, 26.5, 27.8, 38.1, 46.5, 62.4, 159.8; MS (CI+) *m/z* (%): 236 (M+H, 43), 149 (100), 100 (22), 88 (48); HRMS: M+H, found 236.16482, C<sub>14</sub>H<sub>22</sub>O<sub>2</sub>N requires 236.16505. Anal. Calcd for C<sub>14</sub>H<sub>21</sub>O<sub>2</sub>N: C, 71.46; H, 8.99; N, 5.95. Found: C, 71.54; H, 9.12; N, 5.90.

**4.1.35. (*E*)-Ethyl 5-(2,2-dimethyl-3-(2-oxooxazolidin-3-yl)cyclopropyl)-3-methylpent-2-enoate 61.** Pale yellow liquid; IR (mixture of *trans* and *cis*, film):  $\nu_{\max}$  2955, 1759, 1709, 1643 (s) cm<sup>-1</sup>; <sup>1</sup>H NMR (*cis*, 500 MHz, CDCl<sub>3</sub>): δ 0.74 (ddd, *J*=8.9, 7.6, 5.4, 1H, CHCHN), 1.07 (s, 3H, CH<sub>3</sub>CCH<sub>3</sub>), 1.09 (s, 3H, CH<sub>3</sub>CCH<sub>3</sub>), 1.25 (br t, *J*=7.1, 3H, CH<sub>3</sub>CH<sub>2</sub>), 1.34–1.44 (m, 1H, CHHCH<sub>2</sub>), 1.76–1.84 (m, 1H, CHHCH<sub>2</sub>), 2.10 (d, *J*=7.6, 1H, CHN), 2.14 (s, 3H, CH<sub>3</sub>C=CH), 2.16–2.22 (m, 1H, CHHC=CH),

2.23–2.31 (m, 1H, CHHC=CH), 3.43–3.56 (m, 2H, CH<sub>2</sub>N), 4.12 (q, *J*=7.1, 2H, CH<sub>2</sub>CH<sub>3</sub>), 4.22–4.30 (m, 2H, CH<sub>2</sub>OC=O), 5.64 (br s, 1H, CHCOO); <sup>13</sup>C NMR (*cis*, 125 MHz, CDCl<sub>3</sub>): δ 14.3, 14.9, 18.9, 19.5, 22.8, 22.9, 27.0, 27.8, 40.9, 46.9, 59.5, 62.2, 115.8, 159.5, 160.4, 166.7; MS (FAB) *m/z* (%): 296 (M+H, 28), 250 (70), 219 (100), 163 (66), 154 (72); HRMS: M+H, found 296.18541, C<sub>16</sub>H<sub>26</sub>O<sub>4</sub>N requires 296.18617.

**4.1.36. 2-(2-Benzylcyclopropyl)-2,3-dihydro-1-isoindolinone 62.** Pale yellow solid; mp (*trans*) 62–63 °C (*i*-Pr<sub>2</sub>O); IR (mixture of *trans* and *cis*, film):  $\nu_{\max}$  3027 (w), 2914 (w), 1685 (s), 1620 (w), 1496 (w), 1469 (m), 1453 (m), 1408 (m) cm<sup>-1</sup>; <sup>1</sup>H NMR (*trans*, 500 MHz, CDCl<sub>3</sub>): δ 0.93 (td, *J*=7.1, 6.0, 1H, CHHCHN), 1.15 (ddd, *J*=9.6, 6.0, 4.0, CHHCHN), 1.50 (dtdd, *J*=9.6, 7.1, 6.4, 3.4, 1H, CHCHN), 2.67 (dd, *J*=14.7, 7.1, 1H, CHHPh), 2.80–2.89 (m, 2H, CHN and CHHPh), 4.20 (s, 2H, CH<sub>2</sub>Ar), 7.20–7.53 (m, 8H, Ar-*H*), 7.82 (td, *J*=7.5, 1.0, 1H, Ar-*H*); <sup>13</sup>C NMR (*trans*, 125 MHz, CDCl<sub>3</sub>): δ 12.8, 20.0, 31.6, 38.2, 50.1, 122.5, 123.4, 126.2, 127.9, 128.4, 128.4, 131.2, 133.2, 140.6, 140.9, 169.3. <sup>1</sup>H NMR (*cis*, 500 MHz, CDCl<sub>3</sub>): δ 0.90–0.97 (m, 1H), 1.11–1.19 (m, 2H), 2.24 (dd, *J*=15.0, 4.9, 1H, CHHPh), 3.03 (td, *J*=7.5, 4.5, 1H, CHN), 3.15 (dd, *J*=15.0, 4.9, 1H, CHHPh), 4.30 (d, *J*=17.0, 1H, CHHAr), 4.32 (d, *J*=17.0, 1H, CHHAr), 7.17–7.57 (m, 8H, Ar-*H*), 7.88 (td, *J*=7.4, 1.0, 1H, Ar-*H*); <sup>13</sup>C NMR (*cis*, 125 MHz, CDCl<sub>3</sub>): δ 10.6, 19.2, 30.5, 34.0, 51.8, 122.6, 123.6, 125.9, 128.0, 128.3, 128.4, 131.3, 133.1, 141.1, 141.3, 170.3; MS (EI) *m/z* (%): 263 (M<sup>+</sup>, 13), 222 (8), 172 (100), 146 (9), 132 (7), 115 (9), 91 (29), 77 (8), 65 (8), 51 (7); HRMS: M<sup>+</sup>, found 263.13096. C<sub>18</sub>H<sub>17</sub>NO requires 263.13101.

**4.1.37. *N*-Benzyl-*N*-(2-benzylcyclopropyl)acetamide 63.** Colourless oil; IR (mixture of *trans* and *cis*, film):  $\nu_{\max}$  3026 (w), 2924 (w), 1655 (s), 1603 (w), 1495 (w), 1452 (w) cm<sup>-1</sup>; <sup>1</sup>H NMR (*trans*, 500 MHz, CDCl<sub>3</sub>): δ 0.78 (ddd, *J*=7.1, 6.2, 5.5, 1H, CHHCHN), 0.95 (ddd, *J*=9.5, 5.5, 4.0, 1H, CHHCHN), 1.37 (ddtd, *J*=9.5, 7.5, 6.2, 3.5, 1H, CHCHN), 2.16 (s, 3H, Me), 2.33–2.44 (m, 1H, CHN), 2.42 (dd, *J*=14.5, 7.5, 1H, CHCHHPh), 2.66 (dd, *J*=14.5, 6.2, 1H, CHCHHPh), 4.45 (d, *J*=14.8, 1H, CHHPh), 4.53 (d, *J*=14.8, 1H, CHHPh), 7.08–7.12 (m, 4H, Ar-*H*), 7.19–7.31 (m, 6H, Ar-*H*); <sup>13</sup>C NMR (*trans*, 125 MHz, CDCl<sub>3</sub>): δ 15.9, 22.7, 23.3, 36.8, 37.7, 49.6, 126.3, 126.9, 128.4, 128.5, 138.1, 139.7, 173.3; MS (EI) *m/z* (%): 279 (M<sup>+</sup>, 65), 264 (37), 236 (100), 188 (100), 148 (74), 131 (66), 106 (52), 91 (82), 77 (24); HRMS: M<sup>+</sup>, found 279.16205. C<sub>19</sub>H<sub>21</sub>NO requires 279.16231.

**4.1.38. *trans*-3-(2-Benzylcyclopropyl)benzoxazolin-2-one 64.** Pale pink solid; mp 55–57 °C (CH<sub>2</sub>Cl<sub>2</sub>–petrol); IR (film):  $\nu_{\max}$  3063, 3026, 2924, 1771 (s), 1612 (w) cm<sup>-1</sup>; <sup>1</sup>H NMR (*trans*, 400 MHz, CDCl<sub>3</sub>): δ 1.08–1.18 (m, 1H, CHHCHN), 1.30–1.42 (m, 1H, CHHCHN), 1.55–1.70 (m, 1H, CHCHN), 2.73 (dt, *J*=6.7, 3.4, 1H, CHN), 2.76 (dd, *J*=14.5, 7.5, 1H, CHHPh), 2.87 (dd, *J*=14.5, 6.7, 1H, CHHPh), 6.45 (d, *J*=7.5, 1H, Ar-*H*), 6.94–7.40 (m, 8H, Ar-*H*); <sup>13</sup>C NMR (*trans*, 100 MHz, CDCl<sub>3</sub>): 13.3, 21.0, 28.8, 37.9, 109.0, 109.6, 122.2, 123.5, 126.5, 128.6, 128.7, 131.7, 139.7, 142.1, 154.2; MS (EI) *m/z* (%): 265 (M<sup>+</sup>, 65), 224 (25), 175 (55), 130 (100), 115 (50), 103 (90);

HRMS: M+H, found 266.11833. C<sub>16</sub>H<sub>16</sub>NO<sub>2</sub> requires 266.11810.

**4.1.39. endo-3-(1,1a,6,6a-Tetrahydro-cyclopropainden-1-yl)-3H-benzoxazolin-2-one 65.** Pale pink needles; mp 185–186 °C (CH<sub>2</sub>Cl<sub>2</sub>–petrol); IR (film):  $\nu_{\max}$  3042 (w), 3018 (w), 2926 (w), 2853 (w), 1771 (s), 1611 (w) cm<sup>-1</sup>; <sup>1</sup>H NMR (*endo*, 400 MHz, CDCl<sub>3</sub>):  $\delta$  2.35–2.42 (m, 1H, CH<sub>2</sub>CH), 3.06 (t, *J*=6.8, 1H, ArCH), 3.12–3.22 (m, 3H, CH<sub>2</sub> and CHN), 6.82–6.91 (m, 5H, Ar-H), 6.94–6.99 (m, 1H, Ar-H), 7.05 (d, *J*=7.5, 1H, Ar-H), 7.34 (d, *J*=6.8, 1H, Ar-H); <sup>13</sup>C NMR (*endo*, 100 MHz, CDCl<sub>3</sub>):  $\delta$  21.8, 29.5, 32.0, 33.0, 109.6, 109.8, 122.2, 123.1, 123.4, 125.7, 126.1, 126.6, 131.0, 137.7, 142.3, 143.1, 154.5; MS (EI) *m/z* (%): 263 (M+, 65), 192 (30), 148 (40), 129 (100), 115 (50), 102 (32); HRMS: M<sup>+</sup>, found: 263.09589. C<sub>17</sub>H<sub>13</sub>NO<sub>2</sub> requires 263.09462. Anal. Calcd for C<sub>17</sub>H<sub>13</sub>NO<sub>2</sub>: C, 77.55; H, 4.98; N, 5.32. Found: C, 77.10; H, 4.89; N, 5.28.

**4.1.40. trans-1-(2-(Hydroxymethyl)cyclopropyl)pyrrolidin-2-one 67.** Colourless oil; IR (film):  $\nu_{\max}$  3297 (br), 2880, 1674 (s) cm<sup>-1</sup>; <sup>1</sup>H NMR (*trans*, 300 MHz, CDCl<sub>3</sub>):  $\delta$  0.72 (ddd, *J*=7.5, 6.2, 5.9, 1H, CHHCHN), 0.90 (ddd, *J*=9.5, 5.9, 4.3, 1H, CHHCHN), 1.28–1.40 (tddd, *J*=9.5, 6.2, 5.2, 3.5, 1H, CHCH<sub>2</sub>OH), 1.90–2.03 (m, 2H, CH<sub>2</sub>CH<sub>2</sub>N), 2.32–2.41 (m, 3H, CHN and CH<sub>2</sub>CO), 3.15 (dd, *J*=10.9, 9.5, 1H, CHHOH), 3.26–3.38 (m, 2H, CH<sub>2</sub>N), 3.85 (dd, *J*=10.9, 5.2, 1H, CHHOH); <sup>13</sup>C NMR (*trans*, 75 MHz, CDCl<sub>3</sub>):  $\delta$  9.3, 17.8, 22.6, 30.2, 31.3, 47.3, 64.5, 177.0; MS (EI) *m/z* (%): 156 (M+H, 10), 138 (35), 124 (100), 96 (35), 86 (25); HRMS: M<sup>+</sup>, found: 155.09480. C<sub>8</sub>H<sub>13</sub>NO<sub>2</sub> requires 155.09462.

**4.1.41. (±)-1-((1R,2R,6S,7S)-2-Ethoxybicyclo[4.1.0]heptan-7-yl)pyrrolidin-2-one 69.** White solid; mp 95–97 °C (CH<sub>2</sub>Cl<sub>2</sub>–petrol); IR (film):  $\nu_{\max}$  2936 (s), 2864 (s), 1682 (s) cm<sup>-1</sup>; <sup>1</sup>H NMR (*exo*, 500 MHz, CDCl<sub>3</sub>):  $\delta$  0.97–1.06 (m, 1H, CHHCHOEt), 1.06–1.13 (m, 1H, CHHCH<sub>2</sub>CHOEt), 1.17 (t, *J*=6.9, 3H, Me), 1.30–1.36 (m, 1H, CHHCH<sub>2</sub>CHOEt), 1.38–1.48 (m, 2H, CHCHN and CHCHOEt), 1.51–1.62 (m, 2H, CHHCHOEt and CHHCHCHN), 1.80–1.98 (m, 3H, CH<sub>2</sub>CH<sub>2</sub>N and CHHCHCHN), 2.29 (t, *J*=8.2, 2H, CH<sub>2</sub>CON), 2.51 (br t, *J*=3.5, 1H, CHN), 3.26 (br t, *J*=6.8, 2H, CH<sub>2</sub>N), 3.45 (dq, *J*=15.8, 6.9, 1H, CHHO), 3.73 (m, 2H, CHHO and CHO); <sup>13</sup>C NMR (*exo*, 125 MHz, CDCl<sub>3</sub>):  $\delta$  15.5, 17.6, 19.9, 20.5, 21.2, 21.9, 28.0, 31.7, 35.1, 47.5, 63.0, 72.1, 175.7; MS (FAB) *m/z* (%): 224 (M<sup>+</sup>, 48), 178 (100); HRMS: M<sup>+</sup>, found: 224.16480. C<sub>13</sub>H<sub>21</sub>NO<sub>2</sub> requires 224.16505.

**4.1.42. 2-Ethoxycyclohex-1-ene 70.**<sup>23</sup> Sodium hydride (60% dispersion in mineral oil, 954 mg, 23.9 mmol) was added portionwise to a solution of 2-cyclohexen-1-ol (2.21 g, 21.7 mmol) in anhydrous dimethylformamide (15 mL) under nitrogen. After the addition was complete, the reaction was cooled to 0 °C and iodoethane (5.34 mL, 65.0 mmol) was added dropwise (caution: exothermic). The reaction mixture was then allowed to stir at room temperature for 2 h. Water (50 mL) was added and the aqueous mixture was extracted with ether (2×80 mL). The combined organic layers were washed with brine (50 mL), dried (MgSO<sub>4</sub>) and concentrated. The residue was purified by column chromatography (9:1 petrol–Et<sub>2</sub>O) to give the ether as a colourless

liquid (620 mg). Elution of the column with 1:1 Et<sub>2</sub>O–petrol gave the starting alcohol (660 mg); IR (film):  $\nu_{\max}$  3028, 2922 (s), 2655 (s), 1508, 1456 (s) cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  1.21 (t, *J*=6.9, 3H, Me), 1.51–1.58 (m, 1H), 1.67 (dddd, 1H, *J*=12.0, 9.1, 6.3, 2.5), 1.72–1.86 (m, 2H), 1.91–1.98 (m, 1H), 2.00–2.08 (m, 1H), 3.51 (dq, *J*=9.1, 6.9, 1H, CHHMe), 3.57 (dq, *J*=9.1, 6.9, 1H, CHHMe), 3.81–3.86 (m, 1H, CHO), 5.75–5.79 (m, 1H, HC=CH), 5.81–5.86 (m, 1H, HC=CH); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>):  $\delta$  15.8, 19.3, 25.2, 28.4, 63.4, 72.6, 128.0, 130.6.

**4.1.43. 2-(2-tert-Butylcyclopropylamino)ethanol 71.** Lithium hydroxide monohydrate (1.24 g, 29.5 mmol, 30 equiv) was added in one portion to a suspension of cyclopropane **57** (0.18 g, 0.98 mmol, 1 equiv) in a mixture of absolute ethanol (14 mL) and water (6 mL). The reaction mixture was heated at reflux for 20 h and then allowed to cool to room temperature. Most of the ethanol was removed in vacuo and saturated aqueous ammonium chloride (5 mL) was added to the residue. The aqueous layer was extracted with dichloromethane (2×10 mL, then 2×5 mL) and the combined organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated to give the aminoalcohol **71** (75 mg, 0.48 mmol, 49%) as a yellow oil; IR (film):  $\nu_{\max}$  3300 (br), 2953 (s), 2866 (m), 1468 (m) cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  0.34–0.41 (m, 2H, CH<sub>2</sub>CHN), 0.59 (ddd, *J*=9.9, 6.2, 3.5, 1H, CHCHN), 0.77 (s, 9H, 3×Me), 1.95 (dt, *J*=7.2, 3.5, 1H, CHN), 2.71–2.77 (m, 2H, CH<sub>2</sub>N), 2.90 (br s, 2H, OH and NH), 3.57 (t, *J*=5.5, 2H, CH<sub>2</sub>OH); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  9.4, 28.5, 28.9, 31.8, 33.3, 51.1, 60.5; MS (CI) *m/z* (%): 158 (M+H, 100), 100 (86); HRMS: M+H, found 158.154382. C<sub>9</sub>H<sub>20</sub>NO requires 158.15448.

**4.1.44. tert-Butyl N-[(2-tert-butylcyclopropyl)-(2-hydroxyethyl)carbamate 72.** Di-tert-butyl dicarbonate (106 mg, 0.49 mmol, 1.2 equiv) was added portionwise to a solution of aminoalcohol **71** (64 mg, 0.407 mmol, 1 equiv) and triethylamine (0.07 mL, 0.51 mmol, 1.25 equiv) in dry dichloromethane (2 mL) under nitrogen. After stirring for 24 h, the reaction mixture was concentrated in vacuo. The crude product was purified by flash column chromatography (4:1–3:1 petrol–EtOAc) to give the *title compound* **72** (76 mg, 0.295 mmol, 72%) as a colourless oil; IR (film):  $\nu_{\max}$  3450 (br), 2955 (s), 2870 (m), 1685 (s) cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  0.65 (ddd, *J*=9.9, 5.8, 3.9, 1H, CHHCHN), 0.71 (ddd, *J*=7.5, 6.8, 5.8, 1H, CHHCHN), 0.82 (s, 9H, 3×Me), 0.85 (ddd, *J*=9.9, 6.8, 3.9, 1H, CHCHN), 1.42 (s, 9H, OC(CH<sub>3</sub>)<sub>3</sub>), 2.45 (dt, *J*=7.5, 3.9, 1H, CHN), 3.29 (ddd, *J*=14.6, 6.2, 4.6, 1H, CHHN), 3.41 (ddd, *J*=14.6, 6.5, 4.5, 1H, CHHN), 3.57 (m, 2H, CH<sub>2</sub>OH); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>):  $\delta$  12.2, 28.4, 28.4, 29.1, 32.1, 32.2, 50.7, 62.4, 80.1, 158.2; MS (CI+) *m/z* (%): 256 (M–H, 100), 200 (30), 182 (32), 156 (45), 147 (65), 138 (29); HRMS: M–H, found 256.191464. C<sub>14</sub>H<sub>26</sub>NO<sub>4</sub> requires 256.19126.

**4.1.45. [tert-Butoxycarbonyl-(2-tert-butylcyclopropyl)-amino]acetic acid 73.** An aqueous solution of sodium hydroxide (0.5 M in water, 2.2 mL, 1.1 mmol, 4 equiv) and potassium permanganate (0.65 M in water, 1.7 mL, 1.1 mmol, 4 equiv) were added successively to a solution

of alcohol **72** (70 mg, 0.27 mmol, 1 equiv) in *tert*-butanol (2.7 mL). The reaction mixture was stirred for 24 h and then quenched with sodium thiosulfate (5% in water, 7.75 mL). Diethyl ether (10 mL) was added and the mixture was transferred into a separating funnel. The aqueous layer was separated and then acidified to pH 2 with an aqueous hydrochloric acid solution (1 M) at 4 °C. The mixture was then extracted with EtOAc (3×10 mL) and the combined organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated in vacuo to give the *title compound* **73** (62 mg, 0.23 mmol, 84%) as a white amorphous solid; IR (film):  $\nu_{\max}$  3450 (br), 2954 (m), 1699 (s) cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  0.71 (ddd, *J*=9.9, 5.7, 3.9, 1H, *CHHCHN*), 0.75 (ddd, *J*=7.4, 6.7, 5.7, 1H, *CHHCHN*), 0.84 (s, 9H, 3×Me), 0.87 (ddd, *J*=9.9, 6.7, 3.9, 1H, *CHCHN*), 1.44 (s, 9H, OC(CH<sub>3</sub>)<sub>3</sub>), 2.59 (dt, *J*=7.4, 3.9, 1H, CHN), 3.83 (d, *J*=17.7, 1H, *CHHN*), 4.04 (d, *J*=17.7, 1H, *CHHN*), 8.73 (br s, 1H, OH); <sup>13</sup>C NMR (125 MHz, 328 K, CDCl<sub>3</sub>):  $\delta$  12.2, 28.4, 28.4, 29.0, 32.3, 32.5, 50.0, 80.7, 156.7, 175.3; MS (CI+) *m/z* (%): 272 (M+H, 33), 216 (92), 172 (52), 154 (100); HRMS: M+H, found 272.18676. C<sub>14</sub>H<sub>26</sub>NO<sub>4</sub> requires 272.18617.

**4.1.46. 2-(1,1a,6,6a-Tetrahydro-cyclopropa[*a*]inden-1-ylamino)-phenol 74.** Lithium triethylborohydride (1.0 M in THF, 0.75 mL, 0.75 mmol) was added dropwise to a solution of cyclopropane **65** (39 mg, 0.15 mmol) in THF (1 mL) under nitrogen. The reaction mixture was stirred at room temperature overnight and then quenched with saturated ammonium chloride (4 mL). The aqueous mixture was extracted with ethyl acetate (3×10 mL), and the combined organic layers washed with brine (10 mL), dried (MgSO<sub>4</sub>) and concentrated. The residue was purified by column chromatography (1:9 EtOAc–petrol, then 3:7 and 1:1) to give the catecholamine **74** as a pale pink solid (12 mg, 34%); IR (film):  $\nu_{\max}$  3150–3400 (br), 2924, 1659 (s), 1597 cm<sup>-1</sup>; <sup>1</sup>H NMR (*trans*, 500 MHz, CDCl<sub>3</sub>):  $\delta$  2.27 (br q, *J*=6.7, 1H, *CHCH*<sub>2</sub>Ar), 2.50 (d, *J*=18.0, 1H, Ar*CHH*), 3.05 (dd, *J*=8.4, 7.0, 1H, *CHAr*), 3.12 (dd, *J*=18.0, 7.0, 1H, Ar*CHH*), 3.73 (t, *J*=7.0, 1H, *CHNH*), 6.23 (br s, 1H, NH), 6.76–7.30 (m, 8H, Ar-*H*), 8.14 (br s, 1H, OH); <sup>13</sup>C NMR (*trans*, 125 MHz, CDCl<sub>3</sub>):  $\delta$  23.4, 31.3, 31.8, 39.3, 119.6, 120.5, 122.5, 124.5, 124.6, 126.5, 127.0, 127.8, 137.7, 142.7, 150.6, 165.9; MS (CI+) *m/z* (%): 266 (100), 238 (23, M+H), 166 (23); HRMS: M+H, found 238.12343. C<sub>16</sub>H<sub>16</sub>NO requires 238.12318.

**4.1.47. 1-[2-(Hydroxycyclopropyl)]-2-pyrrolidinone 75.** Tetrabutylammonium fluoride (1 M solution in THF, 1.09 mL, 1.09 mmol) was added to a solution of cyclopropylsilane **50** (0.54 mmol) in THF (0.3 mL) under nitrogen. After 30 min of stirring, methanol (1.4 mL), potassium hydrogencarbonate (0.11 g, 1.09 mmol) and hydrogen peroxide (30% solution in water, 1.12 mL, 10.9 mmol) were added to the solution. The reaction mixture was stirred for 18 h and then sodium thiosulfate pentahydrate (2.97 g, 11.97 mmol) was added. After stirring for 30 min the mixture was filtered and concentrated in vacuo. The crude product was then purified by flash column chromatography to give the desired aminocyclopropanol as a colourless oil (35%); IR (film):  $\nu_{\max}$  3369 (br), 2989 (w), 2957 (w), 2859 (w), 1662 (s), 1463, 1425 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz,

CDCl<sub>3</sub>):  $\delta$  0.83 (ddd, *J*=7.5, 7.1, 5.0, 1H, *CHHCHN*), 1.02 (ddd, *J*=8.7, 7.1, 4.1, 1H, *CHHCHN*), 1.85–1.99 (m, 2H, *CH*<sub>2</sub>*CH*<sub>2</sub>N), 2.33 (t, *J*=8.1, 2H, *CH*<sub>2</sub>CO), 2.53 (ddd, *J*=8.7, 5.0, 1.6, 1H, CHN), 3.20–3.30 (m, 2H, *CH*<sub>2</sub>N), 3.50 (ddd, *J*=7.5, 4.1, 1.6, 1H, *CHOH*), 4.31 (br s, 1H, OH); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>):  $\delta$  14.6, 17.9, 31.6, 32.4, 47.4, 51.1, 176.6; MS (EI) *m/z* (%): 141 (M<sup>+</sup>, 7), 112 (100), 98 (24), 84 (23), 69 (47); HRMS: M<sup>+</sup>, found 141.07832. C<sub>7</sub>H<sub>11</sub>NO<sub>2</sub> requires 141.07843.

## Acknowledgements

We would like to thank AstraZeneca for providing a studentship (to G.B.), and the EPSRC for providing both a studentship (to L.J.) and a postdoctoral fellowship (to T.D.S.). We would also like to thank Dr. Abil Aliev for providing advice and assistance with NMR spectroscopy.

## References and notes

- Salaün, J. *Top. Curr. Chem.* **2000**, *207*, 1–67; Salaün, J.; Baird, M. S. *Curr. Med. Chem.* **1995**, *2*, 511–542; Gnad, F.; Reiser, O. *Chem. Rev.* **2003**, *103*, 1603–1623; Stammer, C. H. *Tetrahedron* **1990**, *46*, 2231–2254; Burgess, K.; Ho, K.-K.; Moye-Sherman, D. *Synlett* **1994**, 575–583.
- Vilmaier, E. *The Chemistry of the Cyclopropyl Group*; Rappoport, Z., Ed.; John Wiley & Sons: Chichester, 1987; p 1341.
- Asunskis, J.; Shechter, H. *J. Org. Chem.* **1968**, *33*, 1164–1168; Wurz, R. P.; Charette, A. B. *J. Org. Chem.* **2004**, *69*, 1262–1269.
- Kang, J.; Kim, K. S. *J. Chem. Soc., Chem. Commun.* **1987**, 897–898.
- Aggarwal, V. K.; de Vicente, J.; Bonnert, R. V. *Org. Lett.* **2001**, *3*, 2785–2788; Tsai, C.-C.; Hsieh, I.-L.; Cheng, T.-T.; Tsai, P.-K.; Lin, K.-W.; Yan, T.-H. *Org. Lett.* **2006**, *8*, 2261–2263.
- de Meijere, A.; Kozhushkov, S. I.; Savchenko, A. I. *J. Organomet. Chem.* **2004**, *689*, 2033–2055.
- Brookhart, M.; Studabaker, W. B. *Chem. Rev.* **1987**, *87*, 411–432; Merino, I.; Hegedus, L. S. *Organometallics* **1995**, *14*, 2522–2531; Barluenga, J.; López, S.; Trabanco, A. A.; Flórez, J. *Chem.—Eur. J.* **2001**, *7*, 4723–4729; Barluenga, J.; Aznar, F.; Gutiérrez, I.; García-Granda, S.; Llorca-Baragaño, M. A. *Org. Lett.* **2002**, *4*, 4273–4276.
- Motherwell, W. B.; Roberts, L. R. *J. Chem. Soc., Chem. Commun.* **1992**, 1582–1583; Motherwell, W. B.; Roberts, L. R. *Tetrahedron Lett.* **1995**, *36*, 1121–1124; Motherwell, W. B. *J. Organomet. Chem.* **2001**, *624*, 41–46; Motherwell, W. B. *Pure Appl. Chem.* **2002**, *74*, 135–142.
- Motherwell, W. B.; O’ Mahony, D. J. R.; Popkin, M. E. *Tetrahedron Lett.* **1998**, *39*, 5285–5288.
- Fletcher, R. J.; Motherwell, W. B.; Popkin, M. E. *Chem. Commun.* **1998**, 2191–2192.
- Bégis, G.; Cladingboel, D. E.; Motherwell, W. B. *Chem. Commun.* **2003**, 2656–2657.
- Bégis, G.; Cladingboel, D. E.; Motherwell, W. B.; Sheppard, T. D.; Tocher, D. A. *Synthesis* **2005**, 3186–3188.
- Gmeiner, P.; Bollinger, B. *Synthesis* **1995**, 168–170.
- Norman, M. H.; Minick, D. J.; Rigdon, G. C. *J. Med. Chem.* **1996**, *39*, 149–157.

15. Chan, J. H.-H.; Rickborn, B. *J. Am. Chem. Soc.* **1968**, *90*, 6406–6411; Denmark, S. E.; Edwards, J. P. *J. Org. Chem.* **1991**, *56*, 6974–6981.
16. Tanaka, H.; Ogasawara, K. *Tetrahedron Lett.* **2002**, *43*, 4417–4420.
17. Koldobskii, A. B.; Vakhmistrov, V. E.; Solodova, E. V.; Shilova, O. S.; Kalinin, V. N. *Dokl. Chem. (Engl. Transl.)* **2002**, *387*, 289–292.
18. Treppendahl, S.; Jakobsen, P. *Acta. Chem. Scand. Series B* **1982**, *36*, 275–276.
19. Molander, G. A.; Harris, C. R. *J. Org. Chem.* **1997**, *62*, 2944–2956.
20. Troxler, T.; Scheffold, R. *Helv. Chim. Acta* **1994**, *77*, 1193–1202.
21. Inoue, S.-I.; Takaya, H.; Tani, K.; Otsuka, S.; Sato, T.; Noyori, R. *J. Am. Chem. Soc.* **1990**, *112*, 4897–4905.
22. The alkene **36** was purchased from the Aldrich chemical company (cat. number 35,773-1) but is no longer commercially available.
23. Baguley, P. A.; Walton, J. C. *J. Chem. Soc., Perkin Trans. 1* **1998**, 2073–2082.